0001628280-24-020849.txt : 20240507 0001628280-24-020849.hdr.sgml : 20240507 20240507074331 ACCESSION NUMBER: 0001628280-24-020849 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 24919656 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 10-Q 1 itci-20240331.htm 10-Q itci-20240331
000156751412-312024Q1false48000015675142024-01-012024-03-3100015675142024-05-03xbrli:shares00015675142024-03-31iso4217:USD00015675142023-12-31iso4217:USDxbrli:shares0001567514us-gaap:ProductMember2024-01-012024-03-310001567514us-gaap:ProductMember2023-01-012023-03-310001567514us-gaap:GrantMember2024-01-012024-03-310001567514us-gaap:GrantMember2023-01-012023-03-3100015675142023-01-012023-03-310001567514us-gaap:CommonStockMember2022-12-310001567514us-gaap:AdditionalPaidInCapitalMember2022-12-310001567514us-gaap:RetainedEarningsMember2022-12-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100015675142022-12-310001567514us-gaap:CommonStockMember2023-01-012023-03-310001567514us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001567514us-gaap:RetainedEarningsMember2023-01-012023-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001567514us-gaap:CommonStockMember2023-03-310001567514us-gaap:AdditionalPaidInCapitalMember2023-03-310001567514us-gaap:RetainedEarningsMember2023-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100015675142023-03-310001567514us-gaap:CommonStockMember2023-12-310001567514us-gaap:AdditionalPaidInCapitalMember2023-12-310001567514us-gaap:RetainedEarningsMember2023-12-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001567514us-gaap:CommonStockMember2024-01-012024-03-310001567514us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001567514us-gaap:RetainedEarningsMember2024-01-012024-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001567514us-gaap:CommonStockMember2024-03-310001567514us-gaap:AdditionalPaidInCapitalMember2024-03-310001567514us-gaap:RetainedEarningsMember2024-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001567514us-gaap:SubsequentEventMember2024-04-012024-04-300001567514us-gaap:SubsequentEventMember2024-04-30itci:segment0001567514us-gaap:SalesRevenueNetMemberitci:ThreeMajorWholesalersMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-31xbrli:pure0001567514us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberitci:CustomerOneMember2024-01-012024-03-310001567514us-gaap:SalesRevenueNetMemberitci:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001567514itci:CustomerThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001567514us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberitci:CustomerOneMember2023-01-012023-03-310001567514us-gaap:SalesRevenueNetMemberitci:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001567514itci:CustomerThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001567514us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001567514itci:FDICCertificatesOfDepositMember2024-03-310001567514us-gaap:CertificatesOfDepositMember2024-03-310001567514us-gaap:CommercialPaperMember2024-03-310001567514us-gaap:CorporateDebtSecuritiesMember2024-03-310001567514us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001567514itci:FDICCertificatesOfDepositMember2023-12-310001567514us-gaap:CertificatesOfDepositMember2023-12-310001567514us-gaap:CommercialPaperMember2023-12-310001567514us-gaap:CorporateDebtSecuritiesMember2023-12-310001567514us-gaap:FairValueInputsLevel3Member2024-03-310001567514us-gaap:FairValueInputsLevel3Member2023-12-310001567514us-gaap:CashAndCashEquivalentsMember2024-03-310001567514us-gaap:CashAndCashEquivalentsMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberitci:FDICCertificatesOfDepositMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberitci:FDICCertificatesOfDepositMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-03-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMember2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberitci:FDICCertificatesOfDepositMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberitci:FDICCertificatesOfDepositMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001567514stpr:NY2018-09-300001567514us-gaap:VehiclesMember2024-03-310001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMember2005-05-312024-03-310001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMember2024-03-310001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMember2005-05-310001567514srt:MinimumMemberitci:BristolMyersSquibbCompanyMemberus-gaap:ProductMember2005-05-312005-05-310001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMembersrt:MaximumMember2005-05-312005-05-310001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMember2024-01-012024-03-310001567514us-gaap:PurchaseCommitmentMember2024-03-310001567514us-gaap:PurchaseCommitmentMember2023-12-310001567514itci:InventoriableCostsMember2024-01-012024-03-310001567514itci:InventoriableCostsMember2023-01-012023-03-310001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001567514us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001567514us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-3100015675142023-01-012023-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2023-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001567514us-gaap:RestrictedStockUnitsRSUMember2024-03-310001567514itci:TimeBasedRestrictedStockUnitsRSUMember2024-03-310001567514us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001567514us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001567514us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001567514us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001567514itci:MichaelIHalsteadMember2024-01-012024-03-310001567514itci:RobertVanNostrandMember2024-01-012024-03-310001567514itci:RobertVanNostrandMember2024-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 10-Q
_______________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_________to_________
Commission File Number: 001-36274
_______________________
INTRA-CELLULAR THERAPIES, INC.
(Exact name of registrant as specified in its charter)
_______________________
Delaware36-4742850
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
430 East 29th Street
New York, New York
10016
(Address of principal executive offices)(Zip Code)
(646) 440-9333
(Registrant’s telephone number, including area code)
_______________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common StockITCI
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filero
 
Non-accelerated fileroSmaller reporting companyo
 
  Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of May 3, 2024, the registrant had 105,574,855 shares of common stock outstanding.

Intra-Cellular Therapies, Inc.
Index to Form 10-Q
In this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” and the “Company” mean Intra-Cellular Therapies, Inc. and our subsidiary. “ITI” refers to our wholly-owned subsidiary ITI, Inc.
i
PART I: FINANCIAL INFORMATION
Item 1.    FINANCIAL STATEMENTS
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Balance Sheets (in thousands except share and per share amounts)
March 31, 2024December 31, 2023
(unaudited)
Assets
Current assets:
Cash and cash equivalents$139,819 $147,767 
Investment securities, available-for-sale335,804 350,174 
Restricted cash1,750 1,750 
Accounts receivable, net131,157 114,018 
Inventory15,949 11,647 
Prepaid expenses and other current assets66,048 42,443 
Total current assets690,527 667,799 
Property and equipment, net1,522 1,654 
Right of use assets, net12,481 12,928 
Inventory, non-current34,818 38,621 
Other assets7,688 7,293 
Total assets$747,036 $728,295 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$11,532 $11,452 
Accrued and other current liabilities33,249 27,944 
Accrued customer programs69,972 53,173 
Accrued employee benefits16,409 27,364 
Operating lease liabilities3,639 3,612 
Total current liabilities134,801 123,545 
Operating lease liabilities, non-current12,737 13,326 
Total liabilities147,538 136,871 
Stockholders’ equity:
Common stock, $0.0001 par value: 175,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 97,477,818 and 96,379,811 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
10 10 
Additional paid-in capital2,232,325 2,208,470 
Accumulated deficit(1,632,407)(1,617,160)
Accumulated comprehensive (loss) income
(430)104 
Total stockholders’ equity599,498 591,424 
Total liabilities and stockholders’ equity$747,036 $728,295 
See accompanying notes to these condensed consolidated financial statements.
1
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Operations (in thousands except share and per share amounts) (Unaudited)
Three Months Ended March 31,
20242023
Revenues
Product sales, net$144,843 $94,731 
Grant revenue23 575 
Total revenues, net144,866 95,306 
Operating expenses:
Cost of product sales9,900 6,751 
Selling, general and administrative113,085 98,923 
Research and development42,833 38,024 
Total operating expenses165,818 143,698 
Loss from operations(20,952)(48,392)
Interest income6,064 4,349 
Loss before provision for income taxes(14,888)(44,043)
Income tax expense(359)(10)
Net loss$(15,247)$(44,053)
Net loss per common share:
Basic & Diluted$(0.16)$(0.46)
Weighted average number of common shares:
Basic & Diluted96,875,27595,134,694
See accompanying notes to these condensed consolidated financial statements.
2
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Comprehensive Loss (in thousands) (Unaudited)
Three Months Ended March 31,
20242023
Net loss$(15,247)$(44,053)
Other comprehensive (loss) gain:
Unrealized (loss) gain on investment securities(534)1,492 
Comprehensive loss$(15,781)$(42,561)
See accompanying notes to these condensed consolidated financial statements.
3
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Stockholders’ Equity (in thousands except share and per share amounts) (Unaudited)
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated
Comprehensive
(Loss) Income		Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 202294,829,794$9 $2,137,737 $(1,477,486)$(4,190)$656,070 
Exercise of stock options and issuances of restricted stock849,8271 3,639 — — 3,640 
Stock issued for services408— 22 — — 22 
Share-based compensation—— 10,439 — — 10,439 
Net loss—— — (44,053)— (44,053)
Other comprehensive gain—— — — 1,492 1,492 
Balance at March 31, 202395,680,029$10 $2,151,837 $(1,521,539)$(2,698)$627,610 

Common StockAdditional Paid-in CapitalAccumulated DeficitAccumulated Comprehensive (Loss) IncomeTotal Stockholders’ Equity
SharesAmount
Balance at December 31, 202396,379,811$10 $2,208,470 $(1,617,160)$104 $591,424 
Exercise of stock options and issuances of restricted stock1,097,668— 9,989 — — 9,989 
Stock issued for services339— 23 — — 23 
Share-based compensation—— 13,843 — — 13,843 
Net loss—— — (15,247)— (15,247)
Other comprehensive loss—— — — (534)(534)
Balance at March 31, 202497,477,818$10 $2,232,325 $(1,632,407)$(430)$599,498 
See accompanying notes to these condensed consolidated financial statements.
4
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited)
Three Months Ended March 31,
20242023
Cash flows used in operating activities
Net loss$(15,247)$(44,053)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation132 134 
Share-based compensation13,843 10,439 
Stock issued for services23 22 
Amortization of premiums and accretion of discounts on investment securities, net(2,343)(1,737)
Changes in operating assets and liabilities:
Accounts receivable, net(17,139)(6,356)
Inventory(499)(4,421)
Prepaid expenses and other assets(24,000)(10,557)
Accounts payable80 (1,954)
Accrued and other current liabilities5,305 1,410 
Accrued customer programs16,799 4,271 
Accrued employee benefits(10,955)(6,340)
Operating lease liabilities, net(115)(924)
Net cash used in operating activities(34,116)(60,066)
Cash flows provided by (used in) investing activities
Purchases of investments(81,046)(108,457)
Maturities of investments97,225 91,995 
Net cash provided by (used in) investing activities16,179 (16,462)
Cash flows provided by financing activities
Proceeds from exercise of stock options9,989 3,640 
Net cash provided by financing activities9,989 3,640 
Net (decrease) increase in cash, cash equivalents, and restricted cash(7,948)(72,888)
Cash, cash equivalents, and restricted cash at beginning of period149,517 150,365 
Cash, cash equivalents, and restricted cash at end of period$141,569 $77,477 
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:
March 31,
20242023
Cash and cash equivalents$139,819 $75,727 
Restricted cash1,750 1,750 
Total cash, cash equivalents and restricted cash$141,569 $77,477 
See accompanying notes to these condensed consolidated financial statements.
5
Intra-Cellular Therapies, Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)
March 31, 2024
1. Organization
Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg capsules for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.
In April 2024, the Company completed a public offering of common stock in which the Company sold 7,876,713 shares of common stock at a public offering price of $73.00 per share for aggregate gross proceeds of $575.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $543.0 million. In order to further its commercial activities and research projects and support its collaborations, the Company may require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and working capital needs for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s products, product candidates and technology and, to a much lesser extent, grant funding.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders.
Recent Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.
6
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. For the three-month period ended March 31, 2024, 98% of product sales were generated from three major industry wholesalers.
Three individual customers accounted for approximately 37%, 26%, and 35% as well as 37%, 31%, and 29% of product sales for the three-month periods ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company continues to believe that such customers are of high credit quality.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
3. Investment Securities
Investment securities consisted of the following (in thousands):
March 31, 2024
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$126,577 $41 $(146)$126,472 
FDIC Certificates of Deposit4,165 — (6)4,159 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper62,031 4 (35)62,000 
Corporate Notes/Bonds143,461 37 (325)143,173 
$396,234 $82 $(512)$395,804 
December 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$150,651 $148 $(204)$150,595 
FDIC Certificates of Deposit4,410 2 (12)4,400 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper78,610 59 (27)78,642 
Corporate Notes/Bonds118,899 281 (143)119,037 
$412,570 $490 $(386)$412,674 
7
The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of March 31, 2024 and December 31, 2023, the Company held $93.0 million and $77.8 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year.
The aggregate related fair value of investments with unrealized losses as of March 31, 2024 was $253.5 million, which consisted of $81.3 million from U.S. government agency securities, $3.4 million of certificates of deposit, $56.2 million of commercial paper, and $112.6 million of corporate notes/bonds. $37.8 million of the aggregate fair value of investments with unrealized losses as of March 31, 2024 has been held in a continuous unrealized loss position for over 12 months, with the remaining $215.7 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2023, the aggregate related fair value of investments with unrealized losses was $165.2 million. $70.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2023 had been held in a continuous unrealized loss position for over than 12 months, with the remaining $95.1 million held in a continuous unrealized loss position for less than 12 months.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
4. Fair Value Measurements
The Company applies the fair value method under ASC Topic 820, Fair Value Measurements and Disclosures. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
•Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
•Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
•Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company had no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of March 31, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $31.2 million as of March 31, 2024 and $10.7 million as of December 31, 2023 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in certificates of deposit of $60.0 million as of March 31, 2024 is included in cash and cash equivalents. The carrying value of cash held in U.S. government agency securities of $2.5 million and certificates of deposit of $60.0 million as of December 31, 2023 is included in cash and cash equivalents.
8
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
March 31,
2024		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$31,208 $31,208 $— $— 
U.S. Government Agency Securities126,472 — 126,472 — 
FDIC Certificates of Deposit4,159 — 4,159 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper62,000 — 62,000 — 
Corporate Notes/Bonds143,173 — 143,173 — 
$427,012 $31,208 $395,804 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$10,698 $10,698 $— $— 
U.S. Government Agency Securities150,595 — 150,595 — 
FDIC Certificates of Deposit4,400 — 4,400 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper78,642 — 78,642 — 
Corporate Notes/Bonds119,037 — 119,037 — 
$423,372 $10,698 $412,674 $— 
5. Inventory
Inventory consists of the following (in thousands):
March 31,
2024		December 31,
2023
Raw materials$34,818 $38,621 
Work in process8,875 4,277 
Finished goods7,074 7,370 
Total50,767 50,268 
Less: Current portion(15,949)(11,647)
Total inventory, non-current$34,818 $38,621 
As of March 31, 2024 and December 31, 2023, the Company has recorded $7.8 million and $7.7 million, respectively, in inventory on the condensed consolidated balance sheets which is subject to supplemental regulatory procedures but believes it is probable that it has future economic benefit.
9
6. Prepaid and Other Assets
Prepaid expenses and other assets consist of the following (in thousands):
March 31,
2024		December 31,
2023
Prepaid operating expenses, non-clinical$28,312 $19,465 
Production campaign deposits23,781 15,127 
Clinical trial advances17,076 11,630 
Prefunded customer programs4,567 3,514 
Total73,736 49,736 
Less: Current portion(66,048)(42,443)
Total other assets$7,688 $7,293 
7. Right of Use Assets and Lease Liabilities
In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASC Topic 842, Leases, for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029.
The Company has also entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual vehicle leases, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease, which has been recorded as restricted cash on the condensed consolidated balance sheets.
The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of March 31, 2024 and December 31, 2023:
March 31, 2024December 31, 2023
Other information
Weighted average remaining lease term5.0 years5.3 years
Weighted average discount rate9.07 %9.07 %
The following table presents the lease cost for the three-month periods ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Lease cost
Operating lease cost$941$1,085
Variable lease cost411404
Short-term lease cost536672
$1,888$2,161
10
Maturity analysis under the lease agreements is as follows (in thousands):
Nine months ending December 31, 2024$2,850 
Year ending December 31, 20253,907 
Year ending December 31, 20263,974 
Year ending December 31, 20274,022 
Year ending December 31, 20284,144 
Thereafter1,771 
Total20,668 
Less: Present value discount(4,292)
Total operating lease liability16,376 
Less: Current portion(3,639)
Operating lease liabilities, non-current$12,737 
8. Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (BMS), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company has made payments of $10.8 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
11
Purchase Commitments
The Company enters into certain long-term commitments for goods and services that are outstanding for periods greater than one year. The Company has manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of March 31, 2024, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (API) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory through 2027. The Company has paid deposits of $23.8 million and $15.1 million as of March 31, 2024 and December 31, 2023, respectively, related to these campaigns. Of the $23.8 million balance as of March 31, 2024, $16.2 million is recorded within prepaid expenses and other current assets as the campaigns are expected to be received within one year of the balance sheet date and $7.6 million is recorded within other assets on the condensed consolidated balance sheet as the campaigns are expected to be received after March 31, 2025. Of the $15.1 million balance as of December 31, 2023, $7.9 million is recorded within prepaid expenses and other current assets and $7.2 million is recorded within other assets on the condensed consolidated balance sheet. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements.
9. Share-Based Compensation
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs), granted to employees and directors recognized during the three-month periods ended March 31, 2024 and 2023, was comprised of the following (in thousands):
Three Months Ended March 31,
20242023
Inventoriable costs$417 $342 
Selling, general and administrative9,217 6,980 
Research and development4,209 3,117 
Total share-based compensation expense$13,843 $10,439 
Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (the Amended 2018 Plan) and 2019 Inducement Award Plan (the 2019 Inducement Plan) as of March 31, 2024, and changes during the three-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20234,239,982$28.22 5.2 years
Options granted 2024—
Options exercised 2024(461,857)
Options canceled or expired 2024(5,020)
Outstanding at March 31, 20243,773,105$28.99 5.2 years
Vested and expected to vest at March 31, 20243,773,105$28.99 
Exercisable at March 31, 20243,379,986$26.29 4.9 years
12
The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the three-month period ended March 31, 2024 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20231,645,130$48.92 1.0 year
Time-based RSUs granted in 2024980,422
Time-based RSUs vested in 2024(697,741)
Time-based RSUs cancelled in 2024(12,676)
Outstanding at March 31, 20241,915,135$59.67 1.6 years
As of March 31, 2024, there were $109.6 million of unrecognized compensation costs estimated related to unvested time-based RSUs.
10. Loss Per Share
The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three-month periods ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
Stock options3,773,1054,737,963
RSUs2,139,6371,829,155
13
Item 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed on February 22, 2024. In addition to historical information, the following discussion and analysis includes forward-looking information that involves risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” in our Annual Report on Form 10-K filed on February 22, 2024, as updated from time to time in our subsequent periodic and current reports filed with the SEC.
Overview
We are a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of schizophrenia in adults (42 mg/day) and we initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42 mg/day). We initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg capsules for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). We initiated the commercial launch of these special population doses in August 2022. As used in this report, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.

Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder, or MDD.

In April 2024, we announced positive topline results from our Phase 3 clinical trial, Study 501, evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD. Lumateperone 42 mg given once daily as adjunctive therapy to antidepressants met the primary endpoint in Study 501 by demonstrating a statistically significant and clinically meaningful reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score compared to placebo at Week 6. In the modified intent-to-treat (mITT) study population, the least squares (LS) mean reduction from baseline for lumateperone 42 mg was 14.7 points, versus 9.8 points for placebo (LS mean difference = -4.9 points; p<0.0001; ES= 0.61). Lumateperone 42 mg also met the key secondary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the Clinical Global Impression Scale for Severity of Illness (CGI-S) score compared to placebo at Week 6 (p<0.0001; ES= 0.67). Statistically significant efficacy was seen at the earliest time point tested (Week 1) and maintained throughout the study in both the primary and the key secondary endpoints. In this study, lumateperone 42 mg robustly improved depressive symptoms as reported by patients as measured by the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR-16) (p<0.0001). Lumateperone was generally safe and well-tolerated in this study. The most commonly reported adverse events that were observed at a rate greater than or equal to 5% and at least twice the rate of placebo in the total population were dry mouth (10.8%), fatigue (9.5%) and tremor (5.0%). Adverse events were mostly mild to moderate and resolved within a short period of time. These adverse events were similar to those seen in prior studies of lumateperone as a treatment for bipolar depression and schizophrenia.

Studies 502 and 505 are our global Phase 3 clinical trials evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD. We recently completed clinical conduct in Study 502 and clinical conduct in Study 505 is ongoing. Study 505 is intended to serve as a potential additional registration trial in support of a supplemental New Drug Application, or sNDA, for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD, if needed. We are also conducting an open label roll-over study, Study 503, to assess long-term safety in this patient population, which we expect to complete in the third quarter of 2024. We expect to announce topline results from Study 502 late in the second quarter of 2024 and, subject to such results, we expect to file an sNDA with the FDA for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD in the second half of 2024.

14
In the first quarter of 2020, as part of our lumateperone bipolar depression clinical program, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with bipolar I or bipolar II disorder. Following the positive results in our adjunctive study that was part of our bipolar depression clinical program, Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with bipolar I or bipolar II disorder and mixed features in patients with MDD. In March 2023, we announced positive topline results from Study 403 as lumateperone 42 mg given once daily met the primary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the MADRS total score compared to placebo at Week 6 in the combined patient population of MDD with mixed features and bipolar depression with mixed features (5.7 point reduction vs. placebo; p<0.0001; Cohen’s d effect size (ES) of 0.64). Robust results were also seen in the individual patient population of MDD with mixed features (5.9 point reduction vs. placebo; p<0.0001; ES= 0.67), and in the individual patient population of bipolar depression with mixed features (5.7 point reduction vs. placebo; p<0.0001; ES= 0.64). Additionally, lumateperone 42 mg met the key secondary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the clinician’s assessment of improvement in the overall severity on the CGI-S score compared to placebo at Week 6 in the combined patient population of MDD with mixed features and bipolar depression with mixed features (p<0.0001; ES= 0.59) and in the individual patient population of MDD with mixed features (p=0.0003; ES= 0.57), as well as the individual patient population of bipolar depression with mixed features (p<0.0001; ES=0.61).
We also have an ongoing study, Study 304, evaluating lumateperone for the prevention of relapse in patients with schizophrenia. The study is being conducted in five phases consisting of a screening phase; a 6-week, open-label run-in phase during which all patients will receive 42 mg of lumateperone per day; a 12-week, open-label stabilization phase during which all patients will receive 42 mg of lumateperone per day; a double-blind treatment phase, 26 weeks in duration, during which patients receive either 42 mg of lumateperone per day or placebo (1:1 ratio); and a 2-week safety follow-up phase. This study is being conducted in accordance with our post approval marketing commitment to the FDA in connection with the approval of CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. We expect to complete Study 304 and report topline results in the second half of 2024.
Within the lumateperone portfolio, we have conducted or are in the process of conducting studies with pediatric patients in schizophrenia, bipolar disorder and irritability associated with autism spectrum disorder. Our lumateperone pediatric program includes a double-blind, placebo-controlled study in bipolar depression and two double-blind, placebo-controlled studies in irritability associated with autism spectrum disorder. Additionally, the program includes an open-label safety study in schizophrenia and bipolar disorder. Patient enrollment is ongoing in the open-label safety study as well as in the double-blind, placebo-controlled study in bipolar depression. In addition, we are developing a long-acting injectable, or LAI, formulation to provide more treatment options to patients suffering from mental illness. We have conducted a Phase 1 single ascending dose study with an LAI formulation. This study evaluated the pharmacokinetics, safety and tolerability of a lumateperone LAI in patients with stable symptoms of schizophrenia and was generally safe and well-tolerated. We are evaluating several additional formulations of a lumateperone LAI with treatment durations of one month and longer. We have completed all non-clinical studies to support the initiation of a Phase 1 study with additional formulations of our LAI. We expect to commence clinical conduct in this study in the second half of 2024. Given the encouraging efficacy and favorable safety profile to date with oral lumateperone, we believe that an LAI option, in particular, may lend itself to being an important formulation choice for certain patients.
We are developing ITI-1284-ODT-SL for the treatment of generalized anxiety disorder, psychosis in Alzheimer's disease and agitation in patients with Alzheimer's disease. ITI-1284-ODT-SL is a deuterated form of lumateperone, a new molecular entity formulated as an oral disintegrating tablet for sublingual administration. ITI-1284-ODT-SL is formulated as an oral solid dosage form that dissolves almost instantly when placed under the tongue, allowing for ease of use in the elderly and may be particularly beneficial for patients who have difficulty swallowing conventional tablets. Phase 1 single and multiple ascending dose studies in healthy volunteers and healthy elderly volunteers (> than 65 years of age) evaluated the safety, tolerability and pharmacokinetics of ITI-1284-ODT-SL. In these studies, there were no reported serious adverse events in either age group. In the elderly cohort, reported adverse events were infrequent with the most common adverse event being transient dry mouth (mild). Based on these results, we have initiated Phase 2 programs evaluating ITI-1284-ODT-SL for the treatment of generalized anxiety disorder, psychosis in Alzheimer's disease and agitation in patients with Alzheimer’s disease. The FDA has informed us that they do not believe the deuterated and undeuterated forms of lumateperone are identical. As a result, the non-clinical data from lumateperone may not be broadly applied to ITI-1284-ODT-SL, and we conducted additional toxicology studies. These studies have been completed and we expect to commence clinical conduct in our Phase 2 studies in the first half of 2024. We are continuing with Phase 1 studies with ITI-1284-ODT-SL, including drug-drug interaction studies.
15
We have another major program that has yielded a portfolio of compounds that selectively inhibit the enzyme phosphodiesterase type 1, or PDE1. PDE1 enzymes are highly active in multiple disease states, and our PDE1 inhibitors are designed to reestablish normal function in these disease states. Abnormal PDE1 activity is associated with cellular proliferation and activation of inflammatory cells. Our PDE1 inhibitors ameliorate both of these effects in animal models. We intend to pursue the development of our phosphodiesterase, or PDE, program, for the treatment of aberrant immune system activation in several central nervous system, or CNS, and non-CNS conditions with a focus on diseases where excessive PDE1 activity has been demonstrated and increased inflammation is an important contributor to disease pathogenesis. Our potential disease targets include immune system regulation, neurodegenerative diseases, cancers and other non-CNS disorders. Lenrispodun (ITI-214) is our lead compound in this program. Following the favorable safety and tolerability results in our Phase 1 program, we initiated our development program for lenrispodun for Parkinson’s disease and conducted a Phase 1/2 clinical trial of lenrispodun in patients with Parkinson’s disease to evaluate safety and tolerability in this patient population, as well as motor and non-motor exploratory endpoints. In this study, lenrispodun was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. Our Phase 2 clinical trial of lenrispodun evaluating improvements in motor symptoms, changes in cognition, and inflammatory biomarkers in patients with Parkinson’s disease is ongoing. We expect to report topline results from this study in 2025. We also have an active Investigational New Drug application, or IND, to evaluate our newest candidate within the PDE1 inhibitor program, ITI-1020, as a novel cancer immunotherapy. Our Phase 1 program with ITI-1020 in healthy volunteers is ongoing.
We also have a development program with our ITI-333 compound as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety. There is a pressing need to develop new drugs to treat opioid addiction and safe, effective, non-addictive treatments to manage pain. ITI-333 is a novel compound that uniquely combines activity as an antagonist at serotonin 5-HT2A receptors and a partial agonist at µ-opioid receptors. These combined actions support the potential utility of ITI-333 in the treatment of opioid use disorder and associated comorbidities (e.g., depression, anxiety, sleep disorders) without opioid-like safety and tolerability concerns. We have conducted a Phase 1 single ascending dose study evaluating the safety, tolerability and pharmacokinetics of ITI-333 in healthy volunteers. In this study, ITI-333 achieved plasma exposures at or above those required for efficacy and was generally safe and well-tolerated. We have commenced a neuroimaging study to investigate brain occupancy for receptors that play a role in substance use disorder and also have applicability for pain. The results of this study will support the dose selection for future studies. We also have an ongoing multiple ascending dose study with ITI-333 in healthy volunteers. We have received a grant from the National Institute on Drug Abuse under the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, that we expect will fund a significant portion of the early stage clinical development costs associated with this program.
We also have the ITI-1500 program focused on the development of novel non-hallucinogenic psychedelics. Compounds in this series interact with serotonergic (5-HT2a) receptors in a unique way, potentially allowing the development of this new drug class in mood, anxiety and other neuropsychiatric disorders without the liabilities of known psychedelics including the hallucinogenic potential and risk for cardiac valvular pathologies. Our lead compound in this program, ITI-1549, is currently being evaluated in IND enabling studies.
Results of Operations
The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.
Revenues

Revenues are comprised primarily of net product sales of our commercial product, CAPLYTA, in the United States and is supplemented, to a much lesser extent, by grant revenue from government programs. Our net product sales of CAPLYTA represent sales primarily to wholesalers and specialty distributors and reflect certain adjustments deducted from product sales, gross to arrive at product sales, net.
Expenses
Our operating expenses are comprised of (i) costs of product sales; (ii) selling expenses; (iii) general and administrative expenses; and (iv) research and development expenses.
16
Costs of product sales are comprised of:
•royalty payments on product sales;
•direct costs of formulating, manufacturing and packaging drug product; and
•overhead costs consisting of labor, share-based compensation, shipping, external inventory manufacturing and other miscellaneous operating costs.
Selling expenses are incurred in three major categories:
•salaries, share-based compensation and related benefit costs of a dedicated sales force;
•marketing and promotion expenses; and
•sales operation costs.
General and administrative expenses are incurred in three major categories:
•salaries, share-based compensation and related benefit costs;
•patent, legal and professional costs; and
•office, facilities and infrastructure overhead.
Research and development costs are comprised of:
•fees paid to external parties that provide us with contract services, such as pre-clinical testing, manufacturing and related testing, clinical trial activities and license milestone payments; and
•internal recurring costs, such as costs relating to labor and fringe benefits, share-based compensation, materials, supplies, facilities and maintenance.
The process of researching, developing and commercializing drugs for human use is lengthy, unpredictable and subject to many risks. The costs associated with the commercialization of CAPLYTA are substantial and will be incurred prior to our generating sufficient revenue to offset these costs. Costs for the clinical development of lumateperone-related projects, including for the treatment of MDD, consume and, together with our required post-marketing studies and other anticipated clinical development programs, will continue to consume a large portion of our current, as well as projected, resources. We intend to pursue other disease indications that lumateperone may address, but there are significant costs associated with pursuing FDA approval for those indications, which would include the cost of additional clinical trials.
Product sold through March 31, 2024 consisted of active pharmaceutical ingredient (API) and drug product that was previously charged to research and development expenses prior to FDA approval of CAPLYTA. Because the Company’s policy does not allow for the capitalization of the cost of drug product that was incurred prior to FDA approval, the cost of drug product sold is lower than it would have been and has a positive impact on our cost of product sales for the three-month periods ended March 31, 2024 and 2023. We expect to continue to have this favorable impact on cost of product sales and related product gross margins until the cost of our sales of CAPLYTA include drug product that is manufactured entirely after the FDA approval. We expect that this will be the case for the near term and, as a result, our cost of product sales is less than we anticipate it will be in future periods. In addition, as our net product sales increase in the future and, we exceed certain sales thresholds, the applicable royalty rate for payments we make under our License Agreement with Bristol Myers Squibb (BMS) will increase, which we anticipate will result in an increase to cost of product sales.
We expect that research and development expenses will increase moderately as we proceed with our clinical trials, including increased manufacturing of drug product for clinical trials and pre-clinical development activities. We also expect that our selling, general and administrative costs will increase from prior periods primarily due to costs associated with promotional activities to support the commercial sales of CAPLYTA as well as costs associated with building, maintaining and expanding infrastructure, which will include hiring additional personnel and increasing technological capabilities. We granted significant share-based awards in 2024 and 2023. We expect to continue to grant share-based awards in the future. We expect that our growing employee base will increase our share-based compensation expense in future periods. In addition, inflation has and may continue to affect us by increasing clinical trial and other operational costs. To date, inflation has not had a material impact on our business, but if the global inflationary trends continue, we expect appreciable increases in clinical trial, selling, labor, and other operating costs.
17
The following table sets forth our revenues, operating expenses, interest income and income tax expense for the three-month periods ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Revenues
Product sales, net$144,843 $94,731 
Grant revenue23 575 
Total revenues144,866 95,306 
Expenses
Cost of product sales9,900 6,751 
Selling, general and administrative113,085 98,923 
Research and development42,833 38,024 
Total operating expenses165,818 143,698 
Loss from operations(20,952)(48,392)
Interest income6,064 4,349 
Income tax expense(359)(10)
Net loss$(15,247)$(44,053)
Comparison of Three-Month Periods Ended March 31, 2024 and March 31, 2023
Product Sales, Net
Net product sales were $144.8 million for the three-month period ended March 31, 2024 compared to $94.7 million for the three-month period ended March 31, 2023, which represents an increase of 53%. Net product sales for the periods presented are comprised of sales of CAPLYTA for the treatment of schizophrenia and bipolar depression.
Cost of Product Sales
Cost of product sales was $9.9 million for the three-month period ended March 31, 2024, compared to $6.8 million for the three-month period ended March 31, 2023, which represents an increase of 47%. Cost of product sales consisted primarily of product royalty fees, direct costs and overhead, all of which increased as a result of the increased sales volume.
We expect our product sales in future quarters will continue to be impacted by lower cost of product sales that excludes the cost of the drug product that was incurred prior to FDA approval until our sales of CAPLYTA include drug product that is manufactured entirely after the FDA approval. We expect that this will continue to be the case for the near-term and, as a result, our cost of product sales will be less than we anticipate it will be in future periods. We expect cost of product sales will increase in future quarters as minimum sales thresholds are met, resulting in royalty payment increases under the BMS License Agreement.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the three-month period ended March 31, 2024 were $113.1 million as compared to $98.9 million in the three-month period ended March 31, 2023, which represents an increase of 14%.
Selling costs were $87.7 million for the three-month period ended March 31, 2024 as compared to selling costs of $76.5 million in the same period in 2023, which represents an increase of 15%. This increase is primarily due to increases of salaries, benefits and share-based compensation of $6.5 million, sales force costs of $3.9 million primarily due to the sales force expansion that occurred in the first half of 2023, and professional fees and other costs of $0.8 million. Compensation and related benefit costs for our sales and marketing functions for the three-month periods ended March 31, 2024 and 2023 constituted 32% and 33%, respectively, of our selling costs.
18
General and administrative expenses were $25.4 million for the three-month period ended March 31, 2024 as compared to $22.4 million in the same period in 2023, which represents an increase of 13%. This increase is due to increases in IT related services of $2.5 million and professional fees of $1.0 million, partially offset by a decrease in insurance and other costs of $0.5 million. Compensation and related benefit costs for our general and administrative functions for the three-month periods ended March 31, 2024 and 2023 constituted 24%, respectively, of our general and administrative costs.
Research and Development Expenses
The following tables set forth our research and development expenses for the three-month periods ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
External service costs$30,524 $27,729 
Internal and other costs12,309 10,295 
Total research and development expenses$42,833 $38,024 
Three Months Ended March 31,
20242023
Lumateperone costs$27,603 $24,094 
Non-lumateperone costs7,010 7,534 
Overhead and other costs8,220 6,396 
Total research and development expenses$42,833 $38,024 
Research and development expenses were $42.8 million for the three-month period ended March 31, 2024 as compared to $38.0 million in the same period in 2023, which represents an increase of approximately 13%. This increase is due primarily to increases of $3.5 million for lumateperone costs and $1.8 million for overhead and other costs, partially offset by a decrease of $0.5 million for non-lumateperone costs. External service costs increased by $2.8 million for the period due to the increased lumateperone and non-lumateperone clinical trials as well as other project costs. Internal and other costs increased by $2.0 million for the period due primarily to labor related costs and share-based compensation.
As the development of lumateperone and non-lumateperone programs progresses, we anticipate research and development costs will increase moderately due primarily to non-clinical testing and conducting ongoing and planned clinical trials during the next several years. We are also required to complete non-clinical testing to obtain FDA approval and manufacture materials needed for clinical trial use, which includes non-clinical testing of the drug product, and manufacturing of drug product in anticipation of possible additional FDA approvals of lumateperone for indications beyond schizophrenia and bipolar depression.
The successful development of our product candidates and the approval process requires substantial time, effort and financial resources, and is uncertain and subject to a number of risks. We cannot be certain that any of our product candidates will prove to be safe and effective, will meet all of the applicable regulatory requirements needed to receive and maintain marketing approval, or will be granted marketing approval on a timely basis, if at all. Data from non-clinical studies and clinical trials are susceptible to varying interpretations that could delay, limit or prevent regulatory approval or could result in label warnings related to or recalls of approved products. We, the FDA, or other regulatory authorities may suspend clinical trials at any time if we or they believe that the subjects participating in such trials are being exposed to unacceptable risks or if such regulatory agencies find deficiencies in the conduct of the trials or other problems with our product candidates. Other risks associated with our product candidates are described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, as updated by the section titled “Risk Factors” in this Quarterly Report on Form 10-Q and from time to time in our other periodic and current reports filed with the SEC.
19
Liquidity and Capital Resources
Since inception, we have incurred significant operating and cash losses from our operations. We have primarily funded our operations to date through proceeds from public and private offerings of our common stock and other securities, and to a far lesser extent, through proceeds from grants from government agencies and foundations. In addition, we began to generate net product revenue in the first quarter of 2020 in conjunction with the commercial launch of CAPLYTA.
As of March 31, 2024, our cash and cash equivalents, investment securities, and restricted cash totaled $477.4 million. In April 2024, we completed an underwritten public offering of shares of our common stock in which we sold an aggregate of 7,876,713 shares of common stock at a public offering price of $73.00 per share resulting in net proceeds to us of approximately $543.0 million, after deducting underwriting discounts and commissions and offering expenses. We invest cash in excess of our immediate requirements in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Whenever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances and investments with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such balances because these financial institutions are custodians of our investments.
During the three months ended March 31, 2024, we used $34.1 million of net cash in operating activities, a decrease from $60.1 million of net cash used in operating activities during the three months ended March 31, 2023. The decrease in net cash used in operations was primarily driven by the increased cash receipts in the period related to higher net product sales.
Based on our current operating plans, we expect that our existing cash, cash equivalents, investment securities, and product sales will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the filing date of this quarterly report. During that time, we expect that our expenses will increase, primarily due to the continued commercialization of CAPLYTA for the treatment of schizophrenia and bipolar depression; the pre-commercialization activities, commercialization activities and related infrastructure expansion in connection with the commercialization of CAPLYTA, if approved, for the treatment of MDD; the development of lumateperone in our late-stage clinical programs; the development of our other product candidates, including PDE1 inhibitors, ITI-1284, ITI-333 and ITI-1549; and infrastructure expansion and general operations.
We seek to balance the level of cash, cash equivalents and investments on hand with our projected needs and to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms. Subject to our ability to generate significant revenues from operations, we may need to satisfy our future cash needs through public or private sales of our equity securities, sales of debt securities, incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of our product candidates and technology and, to a lesser extent, grant funding.
We cannot be sure that future funding will be available to us when we need it on terms that are acceptable to us, or at all. We sell securities and incur debt when the terms of such transactions are deemed favorable to us and as necessary to fund our current and projected cash needs. The amount of funding we raise through sales of our common stock or other securities depends on many factors, including, but not limited to, the magnitude of sales of CAPLYTA, the status and progress of our product development programs, projected cash needs, availability of funding from other sources, our stock price and the condition of the capital markets. Due to the volatile nature of the financial markets, equity and debt financing may be difficult to obtain.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
20
If adequate funds are not available to us on a timely basis, we may be required to: (1) delay, limit, reduce or terminate non-clinical studies, clinical trials or other clinical development activities for one or more of our product candidates, including our lead product candidate lumateperone and our other product candidates; (2) delay, limit, reduce or terminate our discovery research or non-clinical development activities; (3) enter into licenses or other arrangements with third parties on terms that may be unfavorable to us or sell, license or relinquish rights to develop or commercialize our product candidates, technologies or intellectual property at an earlier stage of development and on less favorable terms than we would otherwise agree; or (4) limit or reduce commercialization efforts related to CAPLYTA.
Our cash, cash equivalents, and investments are maintained in checking accounts, money market accounts, money market funds, U.S. government agency securities, certificates of deposit, commercial paper, corporate notes and corporate bonds at major financial institutions. Beginning in early 2022, interest rates began to rise, increasing our interest income. These rates began to stabilize in the second half of 2023 and have remained relatively consistent. During the three months ended March 31, 2024, we incurred unrealized losses primarily due to changes in interest rates. Due to the short-term nature of these investments and our intention to hold these investments to maturity, we do not expect to recognize these losses. Even with the rise or further potential rise in interest rates, we do not expect interest income to be a significant source of funding. In addition, our investment portfolio historically has not been adversely impacted by problems in the credit markets, but there can be no assurance that our investment portfolio will not be adversely affected in the future.
Our cash requirements in the short and long term consist of operational, manufacturing, and capital expenditures, a portion of which contain contractual or other obligations. We plan to fund our cash requirements with our current financial resources together with our anticipated receipts from product sales. We manage future cash requirements relative to our long-term business plans. Our primary uses of cash and operating expenses relate to marketing and manufacturing our products, paying employees and consultants, administering clinical trials, and providing technology and facility infrastructure to support our operations.
We have three kinds of long-term contractual commitments - operating leases, licensing and royalty commitments, and purchase obligations. Our operating lease for 32,000 square feet of useable laboratory and office space, as amended, has a term of 14.3 years ending in May 2029. Refer to Note 7 - Right of Use Assets and Lease Liabilities to our condensed consolidated financial statements for further details.
We entered into an exclusive license agreement with BMS for which we are obligated to make tiered single-digit percentage royalty payments on sales of licensed products. The amount of future royalty obligations are dependent on future net product sales of the licensed product. We may also be obligated to make other milestone payments to BMS for each licensed product of up to an aggregate of $14.75 million. Refer to Note 8 - Commitments and Contingencies to our condensed consolidated financial statements for further details.
In addition, we have entered into certain other long-term commitments for goods and services that are outstanding for periods greater than one year including clinical trial agreements. We have certain manufacturing service agreements committing the Company to certain minimum annual purchases through 2029. We also have entered into short-term agreements with various vendors and suppliers of goods and services in the normal course of operations through purchase orders. Such short-term agreements are settled by cash payments upon delivery of goods and services. The nature of the work being conducted under these agreements is such that, in most cases, the services may be stopped on short notice without penalty. In such event, we would not be liable for the full amount of the agreement.
Critical Accounting Policies and Estimates
Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We evaluate our estimates, judgments, and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our critical accounting policies during the three-month period ended March 31, 2024.
21
The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect reported amounts of assets and liabilities as of the date of the balance sheet and reported amounts of revenues and expenses for the periods presented. Judgments must also be made about the disclosure of contingent liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates and under different assumptions or conditions.
Recently Issued Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. We currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.
Certain Factors That May Affect Future Results of Operations
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10-Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the accuracy of our estimates regarding expenses, revenues, uses of cash, cash equivalents and investment securities, capital requirements and the need for additional financing; our expectations regarding our commercialization of CAPLYTA; the supply and availability of and demand for our product; the initiation, cost, timing, progress and results of our development activities, non-clinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approval, or submit an application for regulatory approval, of lumateperone and our other existing product candidates, any product candidates that we may develop, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; our plans to research, develop and commercialize lumateperone and our other current and future product candidates; the election by any collaborator to pursue research, development and commercialization activities; our ability to obtain future reimbursement and/or milestone payments from our collaborators; our ability to attract collaborators with development, regulatory and commercialization expertise; our ability to obtain and maintain intellectual property protection for our product candidates, including through our litigation against the ANDA Filers; our ability to successfully commercialize lumateperone and our other product candidates; the performance of our third-party suppliers and manufacturers and our ability to obtain alternative sources of raw materials; our ability to obtain additional financing; our use of the proceeds from our securities offerings; our exposure to investment risk, interest rate risk, inflation risk, capital market risk, foreign currency fluctuations and geopolitical instability; and our ability to attract and retain key scientific, management, or sales and marketing personnel.
22
Words such as “may,” “anticipate,” “estimate,” “expect,” “may,” “project,” “intend,” “plan,” “believe,” “potential,” “predict,” “project,” “likely,” “will,” “would,” “could,” “should,” “continue” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: there are no guarantees that CAPLYTA will be commercially successful; we may encounter issues, delays or other challenges in commercializing CAPLYTA; whether CAPLYTA receives adequate reimbursement from third-party payors; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indications; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results achieved in CAPLYTA in the treatment of schizophrenia and bipolar depression following commercial launch of the product may be different than observed in clinical trials, and may vary among patients; challenges associated with supply and manufacturing activities, which in each case could limit our sales and the availability of our product; impacts on our business, including on the commercialization of CAPLYTA and our clinical trials, as a result of the conflicts in Ukraine and the Middle East; risks associated with our current and planned clinical trials; we may encounter unexpected safety or tolerability issues with CAPLYTA following commercial launch for the treatment of schizophrenia or bipolar depression or in ongoing or future trials and other development activities; our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials or in clinical trials for other indications; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; there is no guarantee that a generic equivalent of CAPLYTA will not be approved and enter the market before the expiration of our patents; our reliance on collaborative partners and other third parties for development, commercialization, manufacturing or supply of our product and product candidates; risks related to increased interest rates, high rates of inflation, global supply chain disruptions, and geopolitical instability on our business; disruptions resulting from the impact of public health pandemics or epidemics (including, for example, the COVID-19 pandemic), man-made or natural disasters, cybersecurity incidents or other causes; and the other risk factors detailed under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated under the heading “Risk Factors” from time to time in our subsequent periodic and current reports filed with the SEC.
In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form 10-Q or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to the Company or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.
Item 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Sensitivity. As of March 31, 2024, we had cash, cash equivalents, investment securities and restricted cash of approximately $477.4 million, consisting of cash deposited in highly rated financial institutions in the United States and in short-term U.S. Treasury bonds, money market funds, as well as high-grade corporate bonds and commercial paper. The primary objective of our investment activities is to preserve our capital for the purpose of funding operations and we do not enter into investments for trading or speculative purposes. We believe that we do not have material exposure to high-risk investments such as mortgage-backed securities, auction rate securities or other special investment vehicles within our money-market fund investments. We believe that we do not have any material exposure to changes in fair value as a result of changes in interest rates as we intend and have the ability to hold our investments to maturity. Beginning in early 2022, interest rates began to rise, increasing our interest income. These rates began to stabilize in the second half of 2023 and have remained relatively consistent. During the first quarter of 2024, there was an unrealized loss due to increases in interest rates that resulted in a net unrealized loss position of $0.4 million as of March 31, 2024.
Inflation Risk. Inflation generally affects us by increasing our cost of labor, clinical trial costs, and other outsourced activities. To date, inflation has not had a material impact on our business. Should global inflation increase in the future, we expect increases in clinical trial, selling, labor, and other operating costs. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases of our product. Our inability or failure to do so could adversely affect our business, financial condition and results of operations.
23
Capital Market Risk. Although we receive product revenues from commercial sales of CAPLYTA, we may in the future, depend on funds raised through other sources. One possible source of funding is through further securities offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our stock price among other things.
Foreign Currency Risk. Due to our operations outside of the United States, we are exposed to market risk related to changes in foreign currency exchange rates. Historically, our foreign currency exposure has been limited so we have not hedged for this exposure. Changes in the relative values of currencies occur regularly and, in some instances, could materially adversely affect our business, our results of operations or our cash flows. For the three-month periods ended March 31, 2024 and 2023, changes in foreign currency exchange rates did not have a material impact on our historical financial position, our business, our financial condition, our results of operations or our cash flows.
Item 4.    CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
(b) Changes in Internal Controls. There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during the three-month period ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
24
PART II: OTHER INFORMATION
Item 1.    LEGAL PROCEEDINGS
As previously disclosed, in February 2024, we received notices from Alkem Laboratories Ltd., Aurobindo Pharma USA, Inc. and Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Inc. (on behalf of Dr. Reddy’s Laboratories Ltd.), MSN Laboratories Private Ltd., Sandoz Inc., Hetero USA, Inc. (the U.S. Regulatory Agent for Hetero Labs Limited Unit - V, a division of Hetero Labs Limited) and Zydus Pharmaceuticals (USA), Inc., which we refer to as ANDA Filers, that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of generic version of CAPLYTA. The ANDAs each contained Paragraph IV Patent Certifications alleging that certain of our patents covering CAPLYTA are invalid and/or will not be infringed by each ANDA Filer’s manufacture, use or sale of the medicine for which the ANDA was submitted.
Under the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, or the FDCA, we had 45 days from receipt of the notice letters to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court to trigger a stay precluding the FDA’s approval of any ANDA from being effective any earlier than 7.5 years from the date of approval of the CAPLYTA new drug application or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. After conducting the necessary due diligence, and within the 45 day period required under the FDCA, we filed lawsuits on March 27, 2024 and March 28, 2024 in the U.S. Federal District Court for the District of New Jersey against each of the seven generic drug manufacturers who notified us of their ANDA filings. Our lawsuits seek a declaratory judgment that our patents have been infringed by the respective ANDA Filer, an order that any FDA approval of the ANDA Filer's product be not earlier than the date of the expiration of our applicable patents, injunctions against the commercialization of the ANDA Filer's product prior to such expiration date, and an award for attorneys' fees, costs and expenses.
While we intend to vigorously defend and enforce our intellectual property rights protecting CAPLYTA, we can offer no assurance as to when the lawsuits will be decided, whether the lawsuits will be successful, or that a generic equivalent of CAPLYTA will not be approved and enter the market before the expiration of our patents.
Item 1A. RISK FACTORS
There have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 22, 2024.
Item 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Unregistered Sales of Equity Securities
Not applicable.
Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities during the quarter ended March 31, 2024.
Item 3.    DEFAULTS UPON SENIOR SECURITIES
Not applicable.
Item 4.    MINE SAFETY DISCLOSURES
Not applicable.
Item 5.    OTHER INFORMATION

During the fiscal quarter ended March 31, 2024, the following director adopted a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act):

25
•On March 6, 2024, Robert Van Nostrand, a director of the Company, adopted a Rule 10b5-1 Sales Plan. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 20,000 shares of our common stock until June 28, 2024. These 20,000 shares of our common stock are issuable upon the exercise of stock options held by Mr. Van Nostrand that expire on June 30, 2024.

There were no "non-Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K of the Exchange Act) adopted, modified or terminated during the fiscal quarter ended March 31, 2024 by our directors and executive officers.
26
Item 6.    EXHIBITS
Exhibit
Number
Exhibit Description
Filed
Herewith
Incorporated by
Reference herein
from Form
or Schedule
Filing Date
SEC File/
Reg. Number
10.1
X
10.2
X
31.1X
31.2X
32X
101
The following materials from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 (audited), (ii) Condensed Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2024 and 2023, (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited) for the three months ended March 31, 2024 and 2023, (iv) Condensed Consolidated Statements of Stockholders’ Equity (unaudited) for the three months ended March 31, 2024 and 2023, (v) Condensed Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2024 and 2023, and (vi) Notes to Condensed Consolidated Financial Statements (unaudited).
X
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).X

*     Management contract or compensatory plan or arrangement.
27
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INTRA-CELLULAR THERAPIES, INC.
Date: May 7, 2024
By:/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman and Chief Executive Officer
Date: May 7, 2024
By:/s/ Lawrence J. Hineline
Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer
28
 EX-10.1 2 itci-20240321xex101.htm EX-10.1 Document

Exhibit 10.1
INTRA-CELLULAR THERAPIES, INC.
NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
(adopted June 30, 2014; amended March 30, 2016, December 14, 2017, June 18, 2018, February 26, 2020, June 21, 2021, May 5, 2022, April 27, 2023 and April 22, 2024)
The Board of Directors of Intra-Cellular Therapies, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”), which establishes compensation to be paid to non-employee directors of the Company, to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors.
Applicable Persons
This Policy shall apply to each director of the Company who is not an employee of, or compensated consultant to, the Company or any Affiliate (each, an “Outside Director”). “Affiliate” shall mean an entity which is a direct or indirect parent or subsidiary of the Company, as determined pursuant to Section 424 of the Internal Revenue Code of 1986, as amended.
Compensation
A. General Compensation Limits
The following limits shall be in effect for payments and compensation to be paid to each Outside Director:
Annual Equity Grant Limits for Outside Directors:
The Annual Equity Grant (defined below) provided to each Outside Director will not exceed the 75th percentile of the total annual equity awards for the Company’s Outside Director Compensation Peer Group (defined below), based on the total grant date fair value of the equity awards (the “Annual Equity Grant Limit”)
Initial Equity Grant Limits for Newly-Appointed or Elected Outside Directors:
The Initial Equity Grant (defined below) provided to each newly-appointed or elected Outside Director will not exceed 1.75 times the most recent Annual Equity Grant made to Outside Directors, based on the total grant date fair value of the equity awards (the “Initial Equity Grant Limit”)
Grant Date for Annual Equity Awards:The Company will not grant Annual Equity Awards to Outside Directors on the same date that the Company grants annual equity awards to the Company’s executive officers. In addition, any final deliberations or voting on the compensation of the Outside Directors (including any changes to the annual compensation package) will be made at a different Board (or committee) meeting than any final deliberations or voting on the compensation of executive officers (including any changes to the annual compensation package).

The preceding limits will remain in effect until July 1, 2027, unless otherwise amended and approved by a vote of the Company's stockholders.


Outside Director Compensation Peer Group: The Compensation Committee will use its reasonable judgment to select publicly traded, national and regional companies in the biopharmaceutical industries: (a) whose number of employees, stage of development, and relative complexity of clinical trials are similar to the Company’s; (b) that are pre-revenue or had a recent commercial product launch; (c) with market values of approximately 0.25 times to four times the Company’s market capitalization at the time; (d) against which the Company believes it competes for executive talent; and (e) whose compensation and financial data are available in proxy statements or through widely available compensation surveys (as such group is approved by the Compensation Committee, the “Outside Director Compensation Peer Group”). The Compensation Committee will annually (i) assess the Outside Compensation Peer Group and (ii) retain an independent compensation consultant and make a determination as to its independence. The independent compensation consultant will assist in the identification of the Outside Director Compensation Peer Group and will provide an annual update on recent developments and best practices concerning non-employee director and executive compensation matters to the Compensation Committee.
B. Equity Grants

1. Annual Stock Option Grants
Subject to the Annual Equity Grant Limit set forth in Section A above, each Outside Director shall be granted, under the Company’s Amended and Restated 2018 Equity Incentive Plan or any successor plan (the “Equity Plan”), (i) a non-qualified stock option to purchase the number of shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), having an aggregate grant date fair value of $675,000, valued based on a Black-Scholes valuation method (rounded down to the nearest whole share) (an “Annual Option Grant”), (ii) a restricted stock unit for the number of shares of Common Stock, having an aggregate grant date fair value of $675,000, valued based on the closing price of the Common stock on The Nasdaq Global Select Market (or such other securities exchange on which the Common Stock is then traded) (rounded down to the nearest whole share) (an “Annual RSU Grant”) or (iii) a non-qualified stock option to purchase a number of shares of Common Stock and a restricted stock unit for a number of shares of Common Stock having a combined aggregate grant date fair value of $675,000, with the non-qualified stock option valued in accordance with (i) above and the restricted stock unit valued in accordance with (ii) above (an “Annual Option and RSU Grant”), each year on or about the date of the Company’s annual meeting of stockholders (the Annual Option Grant, the Annual RSU Grant or the Annual Option and RSU Grant, as the case may be, the “Annual Equity Grant”); provided that the Annual Equity Grant made in connection with the 2027 Annual Meeting of Stockholders will be made solely in the form of an Annual RSU Grant (and not in the form of an Annual Option Grant or an Annual Option and RSU Grant); and provided, further, that the total aggregate grant date fair value of the Annual Equity Grant, calculated in accordance with this paragraph, shall not exceed the Annual Equity Grant Limit.
The foregoing Annual Equity Grants shall commence with the 2023 Annual Meeting of Stockholders.
2. Initial Stock Option Grants for Newly Appointed or Elected Directors
Subject to the Initial Equity Grant Limit set forth in Section A above, each new Outside Director shall be granted, under the Equity Plan, either (i) a non-qualified stock option to purchase the number of shares of Common Stock having an aggregate grant date fair value of $1,000,000, valued based on a Black-Scholes valuation method (rounded down to the nearest whole share) (an “Initial Option Grant”), (ii) a restricted stock unit for the number of shares of Common Stock, having an aggregate grant date fair value of $1,000,000, valued based on the closing price of the Common stock on The Nasdaq Global Select Market (or such other securities exchange on which the Common Stock is then traded) (rounded down to the nearest whole share) (an “Initial RSU Grant”), or (iii) a non-qualified stock option to purchase a number of shares of Common Stock and a restricted stock unit for a number of shares of Common Stock having a combined aggregate grant date fair value of $1,000,0000, with the non-qualified stock option valued in accordance with (i) above and the restricted stock unit valued in accordance with (ii) above (an “Initial Option and RSU Grant”), on or about the date that the Outside Director is first appointed or elected to the Board of Directors (the Initial Option Grant, the Initial RSU Grant or the Initial Option and RSU Grant, as the case may be, the “Initial Equity Grant”); provided that any Initial Equity Grant made on or after January 1, 2027 will be solely in the form of an Initial RSU Grant (and not an Initial Option Grant or an Initial Option and RSU Grant);


and provided, further, that the total aggregate grant date fair value of the Initial Equity Grant, calculated in accordance with this paragraph, shall not exceed the Initial Equity Grant Limit.
3. Terms of Equity Grants
All Annual Equity Grants and Initial Equity Grants to Outside Directors under this Policy shall vest in one year on the anniversary of the date of grant, subject to the Outside Director’s continued service on the Board of Directors. Annual Option Grants and Initial Option Grants shall have a term of ten years, and shall have an exercise price equal to the fair market value of the Company’s Common Stock as determined under the Equity Plan on the date of grant. The Annual Equity Grants and Initial Equity Grants shall become fully vested immediately prior to a Change of Control (as defined below).
“Change of Control” means the occurrence of any of the following events: (i) any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions; or (ii)(a) a merger or consolidation of the Company whether or not approved by the Board of Directors, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (b) the sale or disposition by the Company of all or substantially all of the Company’s assets in a transaction requiring stockholder approval.
C. Cash Fees or Fully-Vested Stock or Fully Vested Stock Options in Lieu of Cash Fees
1. Annual Cash Fees
The following annual cash fees shall be paid to the Outside Directors serving on the Board of Directors and the Audit Committee, Compensation Committee and Nominating and Governance Committee, as applicable.
Board of Directors or Committee of Board of DirectorsAnnual Retainer
Amount for
Chair (or Lead
Independent
Director, as
applicable)		Annual Retainer
Amount for
Other Members
Board of Directors$80,000 $50,000 
Audit Committee$25,000 $12,000 
Compensation Committee$20,000 $10,000 
Nominating and Governance Committee$12,750 $5,000 

2. Payment Terms for All Cash Fees
Cash fees payable to Outside Directors shall be paid quarterly in arrears as of the last business day of each fiscal quarter.
Following an Outside Director’s first election or appointment to the Board of Directors, such Outside Director shall receive his or her cash compensation pro-rated during the first fiscal quarter in which he or she was initially


appointed or elected for the number of days during which he or she provides service. If an Outside Director dies, resigns or is removed during any quarter, he or she shall be entitled to a cash payment on a pro-rated basis through his or her last day of service that shall be paid on the last business day of the fiscal quarter.
3. Election to Receive Fully-Vested Shares of Common Stock or Fully Vested Stock Options in Lieu of Annual Cash Fees
In lieu of all or a portion of the annual cash fees, an Outside Director may elect by prior written notice to the Company to receive fully-vested shares of Common Stock (a “Stock Award”) or fully-vested non-qualified stock options under the Equity Plan on the last business day of each fiscal quarter for the equivalent value of the cash fees due. Such grant shall be made automatically and without any action on the part of the Board of Directors under the Equity Plan. The number of shares with respect to a Stock Award shall be calculated by dividing the cash fees as determined above by the fair market value of the Common Stock as determined under the Equity Plan on the last business day of each fiscal quarter (rounded down to the nearest whole share). Should the Outside Director elect to receive stock options, the number of shares underlying a stock option shall be calculated by determining the number of shares that is equivalent to the cash fees due as determined above using the Black Scholes value applicable to the Company’s stock option grants calculated on the last business day of each fiscal quarter (rounded down to the nearest whole share). Each stock option grant shall have a term of ten years, unless the Director ceases serving as a member of the Board of Directors, and shall have an exercise price equal to the fair market value of the Company’s Common Stock as determined under the Equity Plan on the date of grant.
Expenses
Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each Outside Director shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection with attending meetings of the Board of Directors and Committees thereof or in connection with other business related to the Board of Directors. Each Outside Director shall abide by the Company’s travel and other expense policies applicable to Company personnel.
Amendments
The Compensation Committee or the Board of Directors shall review this Policy from time to time to assess whether any amendments in the type and amount of compensation provided herein should be adjusted in order to fulfill the objectives of this Policy.


 EX-10.2 3 itci-20240321xex102.htm EX-10.2 Document

Exhibit 10.2

Intra-Cellular Therapies, Inc.
Amended and Restated 2018 Equity Incentive Plan
Performance-Based Restricted Stock Unit Award Grant Notice

1.    Name and Address of Participant:                        
                                            
                
                

2.    Date of Grant of Award (“Date of Grant”):                    

3.    Number of Target Award Shares/PSUs:                        
    
4.    Number of Maximum Award Shares/PSUs:                    

5.    Vesting of Award: Subject to Section 2 of the Performance-Based Restricted Stock Unit Award Agreement (the “Agreement”), which is available via Participant’s [_____] account (such account, the “Electronic Account”), this Performance-Based Restricted Stock Unit Award will vest as follows:

A.    Unless otherwise set forth herein in the event of a Change in Control, the number of Target Award Shares subject to this Performance-Based Restricted Stock Unit Award that shall be earned will be based on the achievement of the TSR Performance Milestone (as defined in Section 6.A below) and the Clinical Performance Milestone (as defined in Section 6.B below) (the “Earned Shares”), which Earned Shares shall vest in full on the date of certification by the Compensation Committee after [______], but on or before [_______], of achievement of such performance milestones, subject to the Participant’s Continuous Service through such vesting date.

B.    In the event of a Change in Control prior to [______], 100% of the TSR Target Award Shares (as defined in Section 6.A below) shall be deemed earned as of the effective date of the Change in Control and such Earned Shares shall vest in full on [______], subject to the Participant’s Continuous Service through such vesting date.

C.    In the event of a Change in Control prior to [______], if the Clinical Target Award Shares (as defined in Section 6.B below) have not previously vested in accordance with Section 5.A above, then 100% of the Clinical Target Award Shares shall be deemed earned as of the effective date of the Change in Control and such Earned Shares shall vest in full on [______], subject to the Participant’s Continuous Service through such vesting date.

6.    Performance Milestones:

A.    TSR Performance Milestone. A total of [___]% of the number of Target Award Shares (the “TSR Target Award Shares”) shall be earned based upon the total shareholder return percentile achievement (“TSR Percentile Achievement”)1 for the [______] year period beginning [______] and ending [______] (the “Performance Period”) of the Company as compared
1 (Price End - Price Begin + Dividends)/Price Begin — with price determined as the average 30 calendar days prior to each measurement date.) For purposes of the foregoing, “Dividends” means any dividends per share that have an ex-dividend date during the Performance Period, assuming the reinvestment of such dividends as of the applicable ex-dividend date.


to the component companies of the Nasdaq Biotechnology Index that are in such Index during the entire Performance Period, with the number of shares of Common Stock (the “Shares”) to be earned pursuant to this Section 6.A determined as follows (the “TSR Performance Milestone”):

[______]

B.    Clinical Performance Milestone. A total of [______]% of the number of Target Award Shares (the “Clinical Target Award Shares”) shall be earned based upon substantial advancement of the Company’s clinical developments programs, including the following (the “Clinical Performance Milestone”), as determined by the Compensation Committee in its sole discretion:


[______]

Any unearned shares shall be returned to the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan (the “Plan”) on the date that the performance milestones are determined.

The Participant must acknowledge receipt of this Performance-Based Restricted Stock Unit Award and agree to its terms and conditions, as set forth in this Performance-Based Restricted Stock Unit Award Grant Notice (this “Grant Notice”), the Electronic Account, the Agreement, and the Plan, by accepting the Performance-Based Restricted Stock Unit Award via the grant acceptance functionality in the Electronic Account within sixty (60) days following the Date of Grant; provided, however, that if the Participant does not accept the Performance-Based Restricted Stock Unit Award within sixty (60) days following the Date of Grant in accordance with the foregoing method, the Participant shall be deemed to have accepted the Performance-Based Restricted Stock Unit Award.

Capitalized terms not explicitly defined in this Grant Notice but defined in the Plan, the Agreement, or the Electronic Account will have the same definitions as in the Plan, the Agreement, or the Electronic Account.


2


Intra-Cellular Therapies, Inc.
Amended and Restated 2018 Equity Incentive Plan
Performance-Based Restricted Stock Unit Award Agreement

This Performance-Based Restricted Stock Unit Award Agreement (this “Agreement”) is made by and between you (the “Participant”) and Intra-Cellular Therapies, Inc. (the “Company”) as of the date of grant set forth in the Performance-Based Restricted Stock Unit Award Grant Notice sent to you under separate cover (the “Grant Notice”) and your [______] account (such date, the “Date of Grant”, and such Grant Notice and account, taken together, the “Account”).

WHEREAS, the Company has adopted the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan (the “Plan”) to promote the interests of the Company by providing an incentive for Employees, Directors and Consultants of the Company and its Affiliates;

WHEREAS, pursuant to the provisions of the Plan, the Company desires to grant to the Participant performance-based restricted stock units (“PSUs”) related to the Company’s Common Stock, in accordance with the provisions of the Plan, all on the terms and conditions hereinafter set forth; and

WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein or in the Account have the meanings ascribed to such terms in the Plan.

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1.    Grant of Award. The Company hereby grants to the Participant an award for the number of PSUs set forth in the Account under “Number of Maximum Award Shares/PSUs” (the “Award”). Each PSU represents a contingent entitlement of the Participant to receive one share of Common Stock, on the terms and conditions and subject to all the limitations set forth in the Account, this Agreement and the Plan. The Participant (a) acknowledges receipt of, and understands and agrees to, the terms and conditions of the Award as set forth in the Account, this Agreement and the Plan and (b) acknowledges receipt of the stock plan prospectus for the Plan.

2.    Vesting of Award.

(a)    Subject to the terms and conditions set forth in this Agreement and the Plan, the Award granted hereby shall vest as set forth in the Account, provided that vesting shall cease upon the termination of the Participant’s Continuous Service.
    
(b)    Except as otherwise set forth in this Agreement:

(i)    If the Participant ceases to be in Continuous Service for any reason prior to the vesting date set forth in the Account, then as of the date on which the Participant’s Continuous Service terminates, all PSUs shall immediately be forfeited to the Company and this Agreement shall terminate and be of no further force or effect.

(ii)    Notwithstanding the foregoing, if (a) the Participant is an Employee at the level of Vice President or above at the time of a termination of the Participant’s Continuous Service and, at any time within ninety (90) days prior to or twelve (12) months following the effective date of a Change in Control (or such other period as is, or may be, set forth in an employment, severance or other similar written agreement between the Participant and the Company or any of its Affiliates), or (b) the Participant is an Employee below the level of Vice President or a Consultant at the time of a termination of the Participant’s Continuous Service and, at any time within twelve (12) months following the effective


date of a Change in Control, the Participant’s Continuous Service terminates by reason of (i) a resignation for Good Reason or (ii) an involuntary termination of the Participant’s Continuous Service without Cause (each, a “Qualifying Termination”), then any shares underlying this Award that have been earned but have not become vested as of the effective date of the Change in Control or if later, as of the date of the Qualifying Termination (whether pursuant to this Agreement or other action of the Board or the Committee) shall become fully vested as of (x) the effective date of the Change in Control if the Participant’s Qualifying Termination occurs prior to the effective date of the Change in Control and (y) the date of such Qualifying Termination if the Participant’s Qualifying Termination occurs on or after the effective date of the Change in Control. In order to give effect to the intent of such accelerated vesting, if the Participant’s Qualifying Termination occurs prior to the effective date of a Change in Control, then notwithstanding anything to the contrary in this Agreement or the Plan, in no event will any portion of this Award or Agreement be forfeited or terminate any earlier than the effective date of the Change in Control. In no event will any unearned shares become vested pursuant to this paragraph.

(c)    Except as otherwise set forth in this Agreement and notwithstanding anything to the contrary in the Plan:

(i)    In the event of a Corporate Transaction that is also a Change in Control, (x) Sections 9(c)(ii) and 9(c)(iii) of the Plan (which provides for certain treatment of Stock Awards upon a Corporate Transaction) will not apply to this Award and (y) for clarity, this Award will be subject to the Change in Control-related provisions set forth in the Account and this Agreement.

(ii)    In the event of a Corporate Transaction that is not also a Change in Control, Section 9(c) of the Plan will apply to this Award; provided, however, that: (x) Section 9(c)(ii) of the Plan (which provides for accelerated vesting in certain circumstances) will apply to this Award only if the Corporate Transaction occurs prior to [______]; and (y) for clarity, if this Award is entitled to accelerated vesting pursuant to the foregoing clause (x) and Section 9(c)(ii) of the Plan, then for purposes of applying such Section, this Award shall be deemed earned at 100% of the number of TSR Target Award Shares and/or the Clinical Target Award Shares, as applicable, and such accelerated vesting shall apply only to such Earned Shares.

(d)    The following terms shall have the following meanings for purposes of this Award:

(i)    “Change in Control” means the occurrence of any of the following events: (i) any “Person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions; or (ii)(a) a merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (b) the sale or disposition by the Company of all or substantially all of the Company’s assets in a transaction requiring stockholder approval.

    (ii)    “Good Reason” means the occurrence of (a) any event constituting “Good Reason” (or an analogous term) as set forth in any employment, consulting, severance or other similar written agreement between the Participant and the Company or any of its Affiliates and (b) any of the following events without the consent of the Participant: (i) if the Participant is an Employee at the level of Vice President or above, a material reduction or change in job duties, responsibilities or authority inconsistent with the Participant’s position with the Company and the Participant’s prior duties,
2


responsibilities or authority immediately prior to the Change in Control; (ii) for any Employee or Consultant, a relocation of the Participant’s primary workplace by more than 25 miles; or (iii) for any Employee or Consultant, a material reduction of the Participant’s base compensation; provided, however, that any event described in clause (b) above shall constitute Good Reason only if (x) the Participant provides the Company with written notice specifying the event alleged to constitute Good Reason within 60 days following the first occurrence of such event, (y) the Company fails to cure such event within 30 days after the Company’s receipt from the Participant of such written notice, and (z) the Participant’s termination of Continuous Service occurs within 30 days following the Company’s failure to cure such event (and in no event later than 120 days following the first occurrence of such event).
3.    Issuance of Shares.

    (a)    The issuance of any shares of Common Stock in respect of this Award is (i) subject to satisfaction of the tax withholding obligations set forth in Section 9 and (ii) intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner. The form of such issuance (e.g., a stock certificate or electronic entry evidencing such shares) will be determined by the Company.

    (b)    In the event one or more PSUs subject to this Award vests, the Company will issue to the Participant, on the applicable vesting date, one share of Common Stock for each PSU that vests on such date (and for purposes of this Agreement, such issuance date is referred to as the “Original Issuance Date”); provided, however, that if the Original Issuance Date falls on a date that is not a business day, such shares will instead be issued to the Participant on the next following business day.

    (c)    Notwithstanding the foregoing, if:

        (i)    this Award is otherwise subject to withholding taxes (as described in Section 9) on the Original Issuance Date,

        (ii)    the Original Issuance Date does not occur (x) during an “open window period” applicable to the Participant, as determined by the Company in accordance with the Company’s then-effective policy on trading in Company securities, or (y) on a date when the Participant is otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market, and

        (iii)    the Company elects, prior to the Original Issuance Date, (x) not to satisfy such withholding taxes by withholding shares of Common Stock from the shares of Common Stock otherwise due, on the Original Issuance Date, to the Participant under this Award, (y) not to permit the Participant to enter into a “same day sale” commitment with a broker-dealer pursuant to Section 9 (including, but not limited to, under a previously established 10b5-1 trading plan entered into in compliance with the Company’s policies), and (z) not to permit the Participant to pay such withholding taxes in cash,

then the shares that would otherwise be issued to the Participant on the Original Issuance Date will not be issued to the Participant on the Original Issuance Date and will instead be issued to the Participant on the first business day when the Participant is not prohibited from selling shares of Common Stock on an established stock exchange or stock market, but in no event later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of the Participant’s taxable year in which the Original Issuance Date occurs), or, if permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the year following the year in which the shares of Common Stock in respect of this Award are no longer subject to a “substantial risk of forfeiture” within the meaning of Treasury Regulations Section 1.409A-1(d).

4.    Prohibitions on Transfer and Sale. This Award (including any additional PSUs received by the Participant as a result of stock dividends, stock splits or any other similar transaction affecting the
3


Company’s securities without receipt of consideration) shall not be transferable by the Participant otherwise than (i) by will or by the laws of descent and distribution, or (ii) pursuant to a qualified domestic relations order as defined by the Internal Revenue Code or Title I of the Employee Retirement Income Security Act or the rules thereunder. Except as provided in the previous sentence, the shares of Common Stock to be issued pursuant to this Agreement shall be issued, during the Participant’s lifetime, only to the Participant (or, in the event of legal incapacity or incompetence, to the Participant’s guardian or representative). This Award shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of this Award or of any rights granted hereunder contrary to the provisions of this Section 4, or the levy of any attachment or similar process upon this Award shall be null and void.

5.    Adjustments. The Plan contains provisions covering the treatment of Stock Awards and shares of Common Stock in a number of contingencies such as Capitalization Adjustments and Corporate Transactions. Provisions in the Plan for adjustment with respect to this Award and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference, subject to the provisions of Section 2 of this Agreement.

6.    Securities Law Compliance. The Participant specifically acknowledges and agrees that any sales of shares of Common Stock shall be made in accordance with the requirements of the Securities Act. The Company currently has an effective registration statement on file with the Securities and Exchange Commission with respect to the Common Stock to be granted hereunder. The Company intends to maintain this registration statement but has no obligation to do so. If the registration statement ceases to be effective for any reason, Participant will not be able to transfer or sell any of the shares of Common Stock issued to the Participant pursuant to this Agreement unless exemptions from registration or filings under applicable securities laws are available. Furthermore, despite registration, applicable securities laws may restrict the ability of the Participant to sell his or her Common Stock, including due to the Participant’s affiliation with the Company. The Company shall not be obligated to either issue the Common Stock or permit the resale of any shares of Common Stock if such issuance or resale would violate any applicable securities law, rule or regulation.

7.    Rights as a Stockholder. The Participant shall have no right as a stockholder, including voting and dividend rights, with respect to the PSUs subject to this Agreement.

8.    Incorporation of the Plan. The Participant specifically understands and agrees that the PSUs and the shares of Common Stock to be issued under the Plan will be issued to the Participant pursuant to the Plan, a copy of which Plan the Participant acknowledges he or she has read and understands and by which Plan he or she agrees to be bound. The provisions of the Plan are incorporated herein by reference, subject to the provisions of Section 2 of this Agreement. In addition, this PSU (and any compensation paid or shares issued pursuant to this Agreement) is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or for a “constructive termination” (or similar term) under any agreement with the Company.

9.    Tax Liability of the Participant and Payment of Taxes. The Participant acknowledges and agrees that any income or other taxes due from the Participant with respect to this Award or the shares of Common Stock to be issued pursuant to this Agreement or otherwise sold shall be the Participant’s responsibility. Without limiting the foregoing, the Participant agrees that if under applicable law the Participant will owe taxes at each vesting or settlement date on the portion of the Award then vested or settled, as applicable, the Company shall be entitled to immediate payment from the Participant of the amount of any tax or other amounts required to be withheld by the Company by applicable law or regulation. Any taxes or other amounts due shall be paid as follows:
4



    (a)    subject to approval by the Board or Committee, as applicable, through reducing the number of shares of Common Stock entitled to be issued to the Participant on the applicable settlement date in an amount not in excess of the maximum amount of tax required to be withheld by law (or such other amount as may be permitted while still avoiding classification of this Award as a liability for financial accounting purposes). Fractional shares will not be retained to satisfy any portion of the Company’s withholding obligation. Accordingly, the Participant agrees that in the event that the amount of withholding required would result in a fraction of a share being owed, that amount will be satisfied by withholding the fractional amount from the Participant’s paycheck;

    (b)    at the option of the Company, by requiring the Participant to deposit with the Company an amount of cash equal to the amount determined by the Company to be required to be withheld with respect to the statutory minimum amount of the Participant’s total tax and other withholding obligations due and payable by the Company or otherwise withholding from the Participant’s paycheck an amount equal to such amounts due and payable by the Company; or

    (c)    if the Company believes that the sale of shares can be made in compliance with applicable securities laws, authorizing, at a time when the Participant is not in possession of material nonpublic information, the sale by the Participant on the applicable vesting date of such number of shares of Common Stock as necessary to sell to satisfy the Company’s withholding obligation, after deduction of the broker’s commission, and the broker shall be required to remit to the Company the cash necessary in order for the Company to satisfy its withholding obligation. To the extent the proceeds of such sale exceed the Company’s withholding obligation, the Company agrees to pay such excess cash to the Participant as soon as practicable. In addition, if such sale is not sufficient to pay the Company’s withholding obligation, the Participant agrees to pay to the Company as soon as practicable, including through additional payroll withholding, the amount of any withholding obligation that is not satisfied by the sale of shares of Common Stock. The Participant agrees to hold the Company and the broker harmless from all costs, damages or expenses relating to any such sale. The Participant acknowledges that the broker is under no obligation to arrange for such sale at any particular price. In connection with such sale of shares of Common Stock, the Participant shall execute any such documents requested by the broker in order to effectuate the sale of shares of Common Stock and payment of the withholding obligation to the Company. The Participant acknowledges that this paragraph is intended to comply with Section 10b5-1(c)(1)(i)(B) under the Exchange Act.

The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.

10.    Participant Acknowledgements and Authorizations.

    The Participant acknowledges the following:

    (a)    The Company is not by the Plan or this Award obligated to continue the Participant as an employee, director or consultant of the Company or an Affiliate.

    (b)    The Plan is discretionary in nature and may be suspended or terminated by the Company at any time.

    (c)    The grant of this Award is considered a one-time benefit and does not create a contractual or other right to receive any other award under the Plan, benefits in lieu of awards or any other benefits in the future.

    (d)     The Plan is a voluntary program of the Company and future awards, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the amount of any award, vesting provisions and the purchase price, if any.
5



    (e)    The value of this Award is an extraordinary item of compensation outside of the scope of the Participant’s employment or consulting contract, if any. As such the Award is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments. The future value of the shares of Common Stock is unknown and cannot be predicted with certainty.

        (f)    The Participant (i) authorizes the Company and each Affiliate and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of the Award and the administration of the Plan; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

11.    Notices. Any notices provided for in this Agreement or the Plan shall be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to the Participant, five days after deposit in the U.S. mail, postage prepaid, addressed to the Participant at the last address the Participant provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Agreement by electronic means or to request the Participant’s consent to participate in the Plan by electronic means. By accepting the Award in accordance with the procedures described in Section 18 of this Agreement, the Participant consents to receive such documents by electronic delivery and to participate in the Plan through an online or electronic system established and maintained by the Company or another third party designated by the Company.

12.    Assignment and Successors.

    (a)    This Agreement is personal to the Participant and without the prior written consent of the Company shall not be assignable by the Participant otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Participant’s legal representatives.

    (b)    This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

13.    Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in the state of New York and agree that such litigation shall be conducted in the state courts of the state of New York or the federal courts of the United States for the District of Manhattan.

14.    Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and enforceable, and to the extent that this is impossible, then such provision shall be deemed to be excised from this Agreement, and the validity, legality and enforceability of the rest of this Agreement shall not be affected thereby.

15.    Entire Agreement. This Agreement, together with the Plan and the terms and conditions of the Award as set forth in the Account, constitutes the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof, with the exception of any employment, severance or other similar written agreement that would provide for more favorable vesting acceleration or other treatment of this Award upon the terms and conditions set forth therein (in which case such terms
6


and conditions shall apply to this Award instead of the applicable terms and conditions of this Agreement); provided, however, that notwithstanding anything to the contrary in such agreement, any such vesting acceleration or other treatment shall apply only to the number of Target Award Shares subject to this Award. No statement, representation, warranty, covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict the express terms and provisions of this Agreement; provided, however, in any event, this Agreement shall be subject to and governed by the Plan.

16.    Modifications and Amendments; Waivers and Consents. The terms and provisions of this Agreement may be modified or amended as provided in the Plan. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

Notwithstanding the foregoing or anything set forth in the Account, this Agreement or the Plan to the contrary, the Compensation Committee will have the authority to reduce the number of shares of Common Stock subject to this Award that are deemed earned (and, therefore, that may vest) from the number otherwise calculated under the terms set forth in the Account or this Agreement and may take into consideration such other factors as it determines appropriate, in its sole discretion, in determining the number of shares of Common Stock subject to this Award that are deemed earned (and, therefore, that may vest).

    17.    Section 409A. The Award of PSUs evidenced by this Agreement is intended to be exempt from the nonqualified deferred compensation rules of Section 409A of the Code as a “short term deferral” (as that term is used in the final regulations and other guidance issued under Section 409A of the Code, including Treasury Regulation Section 1.409A-1(b)(4)(i)), and shall be construed accordingly. However, if (i) this Award fails to satisfy the requirements of the short-term deferral rule and is otherwise not exempt from, and therefore deemed to be deferred compensation subject to, Section 409A of the Code, (ii) the Participant is deemed by the Company at the time of the Participant’s “separation from service” (as such term is defined in Treasury Regulations Section 1.409A-1(h) without regard to any alternative definition thereunder) to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, and (iii) any of the payments set forth herein are issuable upon such separation from service, then to the extent delayed commencement of any portion of such payments is required to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code and the related adverse taxation under Section 409A of the Code, such payments will not be provided to the Participant prior to the earliest of (a) the date that is six (6) months and one (1) day after the date of such separation from service, (b) the date of the Participant’s death, or (c) such earlier date as permitted under Section 409A of the Code without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 17 will be paid in a lump sum to the Participant, and any remaining payments due will be paid as otherwise provided herein. Each installment of PSUs that vests under this Award is a “separate payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2).

    18.    Acceptance. The Participant must acknowledge receipt of the Award and agree to its terms and conditions, as set forth in the Account, this Agreement and the Plan, by accepting the Award via the grant acceptance functionality in the Account within sixty (60) days following the Date of Grant; provided, however, that if the Participant does not accept the Award within sixty (60) days following the Date of Grant in accordance with the foregoing method, the Participant shall be deemed to have accepted the Award.

7


*    *    *

8

 EX-31.1 4 itci-20240331xex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS UNDER SECTION 302
I, Sharon Mates, Ph.D., certify that:
1.I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 7, 2024
/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman and Chief Executive Officer
(principal executive officer)

 EX-31.2 5 itci-20240331xex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS UNDER SECTION 302
I, Lawrence J. Hineline, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 7, 2024
/s/ Lawrence J. Hineline
Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer
(principal financial officer)

 EX-32 6 itci-20240331xex32.htm EX-32 Document

Exhibit 32
CERTIFICATIONS UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intra-Cellular Therapies, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Quarterly Report for the quarter ended March 31, 2024 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 7, 2024
/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman, President and Chief Executive Officer
(principal executive officer)
Dated: May 7, 2024
/s/ Lawrence J. Hineline
Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer
(principal financial officer)

EX-101.SCH 7 itci-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Investment Securities link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Prepaid and Other Assets link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Right of Use Assets and Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Investment Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Prepaid and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Loss Per Share - (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Organization - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Investment Securities - Summary of Investment Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Investment Securities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Prepaid and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Prepaid and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 itci-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 itci-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 itci-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Range [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Outstanding at beginning of year, Number of Shares (in shares) Outstanding at end of year, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Schedule of Investment Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Exercisable at end of period, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restatement Determination Date: Restatement Determination Date [Axis] Clinical trial advances Clinical Trial Advances Clinical Trial Advances Corporate Notes/Bonds Corporate Debt Securities [Member] Purchases of investments Payments to Acquire Investments Insider Trading Policies and Procedures [Line Items] Exercisable at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Net proceeds Proceeds from Issuance of Common Stock Right of Use Assets and Lease Liabilities Right Of Use Assets And Lease Liabilities [Text Block] Right of use assets and lease liabilities. Exercise of stock options and issuances of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Weighted-Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Outstanding at beginning of period, Number of Shares (in shares) Outstanding at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Accrued employee benefits Accrued Employee Benefits, Current Trading Symbol Trading Symbol U.S. Government Agency Securities US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Payment of milestone amount Possible Milestone Payments Remaining Payment of milestone amount. Purchase Commitment Purchase Commitment [Member] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Unrealized (Losses) Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Options exercised, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Executive Category: Executive Category [Axis] Other assets Deposits Assets, Noncurrent Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Certificates of Deposit Certificates of Deposit [Member] Investment Type [Axis] Investment Type [Axis] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Investments [Domain] Investments [Domain] Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Selling, general and administrative Selling, General and Administrative Expenses [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease liabilities, non-current Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Thereafter Lessee Operating Lease Liability Payments Due after Year Four Lessee operating lease liability payments due after Year four. RSUs Restricted Stock Units (RSUs) [Member] Summary of Information Regarding RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation Depreciation Income Statement Location [Axis] Income Statement Location [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Schedule Of Maturity Analysis Under Lease Agreements Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction FDIC Certificates of Deposit FDIC Certificates Of Deposit [Member] FDIC certificates of deposit. Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventory Increase (Decrease) in Inventories Unrealized (loss) gain on investment securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Research and development Research and Development Expense [Member] Cash flows provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Schedule of Quantitative Information About Operating Leases Schedule of Quantitative Information About Operating Leases [Table Text Block] Schedule of Quantitative Information About Operating Leases Number of anti-dilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Time based RSU's granted, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Unrecognized compensation costs related to unvested RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Outstanding at end of period, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Arrangement: Trading Arrangement [Axis] Less: Present value discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating lease liabilities Less: Current portion Operating Lease, Liability, Current Prepaid operating expenses, non-clinical Prepaid Operating Expenses, Non-Clinical Prepaid Operating Expenses, Non-Clinical Entity Shell Company Entity Shell Company Year ending December 31, 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] Year ending December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Offering price (in dollars per share) Sale of Stock, Price Per Share Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease cost Variable Lease, Cost Operating lease cost Operating Lease, Cost Weighted average number of common shares: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate fair value of investments with unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Time based RSU's vested, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Security Exchange Name Security Exchange Name Assets measured using quoted prices Available-for-sale investment securities Assets, Fair Value Disclosure Aggregate gross proceeds Sale of Stock, Consideration Received on Transaction Accumulated comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Carrying value of cash held in commercial paper, government securities US Government Agencies Securities, at Carrying Value Stock options Share-Based Payment Arrangement, Option [Member] Employee Stock Option [Member] Maximum Maximum [Member] Customer Three Customer Three [Member] Customer three. Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Short-term lease cost Short-Term Lease, Cost Entity Address, Address Line One Entity Address, Address Line One Accrued and other current liabilities Accrued Liabilities and Other Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Subsequent Event Subsequent Event [Member] Customer Concentration Risk Customer Concentration Risk [Member] Customer Two Customer Two [Member] Customer two. Income Statement [Abstract] Income Statement [Abstract] Other current assets Deposits Assets, Current Raw materials Inventory, Raw Materials, Net of Reserves Operating expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share) Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Production campaign deposits Deposit Assets Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventory Less: Current portion Inventory, Net Total lease cost Lease, Cost Range [Axis] Statistical Measurement [Axis] Inventory, non-current Total inventory, non-current Inventory, Noncurrent Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Prefunded customer programs Prefunded Customer Program Prefunded Customer Program Total Shareholder Return Amount Total Shareholder Return Amount Product sales, net Product Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash flows used in operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Customer One Customer One [Member] Customer one. Certificates of deposits Certificates of Deposit, at Carrying Value PEO PEO [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Asset Class [Domain] Asset Class [Domain] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Company made an upfront payment Collaborative Agreement Upfront Payments Collaborative Agreement Upfront Payments Name of Property [Domain] Name of Property [Domain] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total operating lease liability Operating Lease, Liability Total liabilities Liabilities Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Aggregate related fair value of investments with unrealized losses Debt Securities, Available-for-Sale, Unrealized Loss Position Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Net loss per common share: Earnings Per Share [Abstract] Other information Other Information [Abstract] Other information. Common stock, $0.0001 par value: $175,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; $97,477,818 and $96,379,811 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Continuous unrealized losses, value remaining Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Robert Van Nostrand [Member] Robert Van Nostrand Stock issued for services Issuance of Stock and Warrants for Services or Claims All Individuals All Individuals [Member] Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date PEO Name PEO Name Concentration risk (as a percent) Concentration Risk, Percentage Restricted cash Restricted Cash, Current Prepaid Expenses and Other Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Significant Accounting Policies Significant Accounting Policies [Policy Text Block] Significant accounting policies. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Investment securities, available-for-sale Debt Securities, Available-for-Sale, Current Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization consolidation and presentation of financial statements disclosure. Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Accrued employee benefits Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Commercial Paper Commercial Paper [Member] Obliged to make milestone payments Collaborative Arrangement Amount Payable Collaborative arrangement amount payable. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Prepaid and Other Assets Other Assets Disclosure [Text Block] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Revenue Recognition, Multiple-deliverable Arrangements [Table] Revenue Recognition, Multiple-deliverable Arrangements [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization consolidation and presentation of financial statements disclosure. Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Year ending December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Year ending December 31, 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share) Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Total share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Options granted, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Investment securities, available for sale, noncurrent Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Loss Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Term of long term lease Lessee, Operating Lease, Term of Contract Minimum Minimum [Member] Property and equipment, net Property, Plant and Equipment, Net Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Cash paid Cash Other comprehensive gain (loss) Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Liabilities measured using quoted prices Liabilities, Fair Value Disclosure Operating lease liabilities, net Increase (Decrease) in Operating Lease Liability Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Amortization of premiums and accretion of discounts on investment securities, net Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Other assets Total other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic (in dollars per share) Earnings Per Share, Basic Right of use assets, net Operating Lease, Right-of-Use Asset Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Nine months ending December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Inventory subject to supplemental regulatory procedures Inventory, Net, Subject To Supplemental Regulatory Procedures Inventory, Net, Subject To Supplemental Regulatory Procedures Purchase Commitment, Excluding Long-Term Commitment [Domain] Purchase Commitment, Excluding Long-Term Commitment [Domain] Michael I. Halstead [Member] Michael I. Halstead Stock issued for services Stock Issued During Period, Value, Issued for Services Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Cost of product sales Cost Of Product Sales Cost of product sales. Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Estimated Fair Value Debt Securities, Available-for-Sale Inventoriable costs Inventoriable Costs [Member] InventoriableCostsMember. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Accrued customer programs Increase Decrease In Accrued Customer Programs Increase decrease in accrued customer programs. Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] NEW YORK NEW YORK Investment Securities Investment [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Other comprehensive (loss) gain: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prepaid expenses and other current assets Less: Current portion Prepaid Expense and Other Assets, Current Time based RSU's cancelled, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Exercise of stock options and issuances of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key License expiration period Collaborative Arrangement License Expiration Term Collaborative arrangement license expiration description. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax expense Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Restricted stock outstanding, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Time Based Restricted Stock Units Time Based Restricted Stock Units R S U [Member] Time based restricted stock units. Fair Value Measurements Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Revenue Benchmark Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory Inventory Disclosure [Text Block] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Total revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Money Market Funds Money Market Funds [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Stock issued for services (in shares) Stock Issued During Period, Shares, Issued for Services Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Royalty payment, percentage (as a percent) Royalty Payment Percentage Royalty Payment Percentage Diluted (in share) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Carrying value of cash held in money market funds Money Market Funds, at Carrying Value Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Vehicle Lease Vehicles [Member] Lease cost Lease, Cost [Abstract] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Cover [Abstract] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Grant revenue Grant [Member] Non-NEOs Non-NEOs [Member] Options canceled or expired, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Total Lessee, Operating Lease, Liability, to be Paid Total operating expenses Operating Expenses Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows provided by financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Three Major Wholesalers Three Major Wholesalers [Member] Three Major Wholesalers Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Loss from operations Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Bristol-Myers Squibb Company Bristol Myers Squibb Company [Member] Bristol Myers Squibb company. Cash and Cash Equivalents Cash and Cash Equivalents [Member] Total Prepaid Expense and Other Assets Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Vested or expected to vest at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Accrued customer programs Accrued Customer Programs Current Accrued customer programs current. Guarantor obligations, value Guarantor Obligations, Current Carrying Value Name of Property [Axis] Name of Property [Axis] Total Inventory, Current And Noncurrent, Net Of Reserves Inventory, Current And Noncurrent, Net Of Reserves EX-101.PRE 11 itci-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page - shares
 3 Months Ended
Mar. 31, 2024
May 03, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-36274  
Entity Registrant Name INTRA-CELLULAR THERAPIES, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 36-4742850  
Entity Address, Address Line One 430 East 29th Street  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10016  
City Area Code 646  
Local Phone Number 440-9333  
Title of 12(b) Security Common Stock  
Trading Symbol ITCI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   105,574,855
Entity Central Index Key 0001567514  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 139,819 $ 147,767
Investment securities, available-for-sale 335,804 350,174
Restricted cash 1,750 1,750
Accounts receivable, net 131,157 114,018
Inventory 15,949 11,647
Prepaid expenses and other current assets 66,048 42,443
Total current assets 690,527 667,799
Property and equipment, net 1,522 1,654
Right of use assets, net 12,481 12,928
Inventory, non-current 34,818 38,621
Other assets 7,688 7,293
Total assets 747,036 728,295
Current liabilities:    
Accounts payable 11,532 11,452
Accrued and other current liabilities 33,249 27,944
Accrued customer programs 69,972 53,173
Accrued employee benefits 16,409 27,364
Operating lease liabilities 3,639 3,612
Total current liabilities 134,801 123,545
Operating lease liabilities, non-current 12,737 13,326
Total liabilities 147,538 136,871
Stockholders’ equity:    
Common stock, $0.0001 par value: $175,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; $97,477,818 and $96,379,811 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 10 10
Additional paid-in capital 2,232,325 2,208,470
Accumulated deficit (1,632,407) (1,617,160)
Accumulated comprehensive (loss) income (430) 104
Total stockholders’ equity 599,498 591,424
Total liabilities and stockholders’ equity $ 747,036 $ 728,295
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 175,000,000 175,000,000
Common stock, shares issued (in shares) 97,477,818 96,379,811
Common stock, shares outstanding (in shares) 97,477,818 96,379,811
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenues, net $ 144,866 $ 95,306
Operating expenses:    
Cost of product sales 9,900 6,751
Selling, general and administrative 113,085 98,923
Research and development 42,833 38,024
Total operating expenses 165,818 143,698
Loss from operations (20,952) (48,392)
Interest income 6,064 4,349
Loss before provision for income taxes (14,888) (44,043)
Income tax expense (359) (10)
Net loss $ (15,247) $ (44,053)
Net loss per common share:    
Basic (in dollars per share) $ (0.16) $ (0.46)
Diluted (in dollars per share) $ (0.16) $ (0.46)
Weighted average number of common shares:    
Basic (in shares) 96,875,275 95,134,694
Diluted (in share) 96,875,275 95,134,694
Product sales, net    
Total revenues, net $ 144,843 $ 94,731
Grant revenue    
Total revenues, net $ 23 $ 575
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net loss $ (15,247) $ (44,053)
Other comprehensive (loss) gain:    
Unrealized (loss) gain on investment securities (534) 1,492
Comprehensive loss $ (15,781) $ (42,561)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2022   94,829,794      
Beginning balance at Dec. 31, 2022 $ 656,070 $ 9 $ 2,137,737 $ (1,477,486) $ (4,190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   849,827      
Exercise of stock options and issuances of restricted stock 3,640 $ 1 3,639    
Stock issued for services (in shares)   408      
Stock issued for services 22   22    
Share-based compensation 10,439   10,439    
Net loss (44,053)     (44,053)  
Other comprehensive gain (loss) 1,492       1,492
Ending balance (in shares) at Mar. 31, 2023   95,680,029      
Ending balance at Mar. 31, 2023 627,610 $ 10 2,151,837 (1,521,539) (2,698)
Beginning balance (in shares) at Dec. 31, 2023   96,379,811      
Beginning balance at Dec. 31, 2023 591,424 $ 10 2,208,470 (1,617,160) 104
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   1,097,668      
Exercise of stock options and issuances of restricted stock 9,989   9,989    
Stock issued for services (in shares)   339      
Stock issued for services 23   23    
Share-based compensation 13,843   13,843    
Net loss (15,247)     (15,247)  
Other comprehensive gain (loss) (534)       (534)
Ending balance (in shares) at Mar. 31, 2024   97,477,818      
Ending balance at Mar. 31, 2024 $ 599,498 $ 10 $ 2,232,325 $ (1,632,407) $ (430)
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows used in operating activities    
Net loss $ (15,247) $ (44,053)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 132 134
Share-based compensation 13,843 10,439
Stock issued for services 23 22
Amortization of premiums and accretion of discounts on investment securities, net (2,343) (1,737)
Changes in operating assets and liabilities:    
Accounts receivable, net (17,139) (6,356)
Inventory (499) (4,421)
Prepaid expenses and other assets (24,000) (10,557)
Accounts payable 80 (1,954)
Accrued and other current liabilities 5,305 1,410
Accrued customer programs 16,799 4,271
Accrued employee benefits (10,955) (6,340)
Operating lease liabilities, net (115) (924)
Net cash used in operating activities (34,116) (60,066)
Cash flows provided by (used in) investing activities    
Purchases of investments (81,046) (108,457)
Maturities of investments 97,225 91,995
Net cash provided by (used in) investing activities 16,179 (16,462)
Cash flows provided by financing activities    
Proceeds from exercise of stock options 9,989 3,640
Net cash provided by financing activities 9,989 3,640
Net (decrease) increase in cash, cash equivalents, and restricted cash (7,948) (72,888)
Cash, cash equivalents, and restricted cash at beginning of period 149,517 150,365
Cash, cash equivalents, and restricted cash at end of period $ 141,569 $ 77,477
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Statement of Cash Flows [Abstract]        
Cash and cash equivalents $ 139,819 $ 147,767 $ 75,727  
Restricted cash 1,750 1,750 1,750  
Total cash, cash equivalents and restricted cash $ 141,569 $ 149,517 $ 77,477 $ 150,365
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg capsules for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.
In April 2024, the Company completed a public offering of common stock in which the Company sold 7,876,713 shares of common stock at a public offering price of $73.00 per share for aggregate gross proceeds of $575.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $543.0 million. In order to further its commercial activities and research projects and support its collaborations, the Company may require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and working capital needs for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s products, product candidates and technology and, to a much lesser extent, grant funding.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders.
Recent Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. For the three-month period ended March 31, 2024, 98% of product sales were generated from three major industry wholesalers.
Three individual customers accounted for approximately 37%, 26%, and 35% as well as 37%, 31%, and 29% of product sales for the three-month periods ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company continues to believe that such customers are of high credit quality.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investment Securities
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Investment Securities Investment Securities
Investment securities consisted of the following (in thousands):
March 31, 2024
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$126,577 $41 $(146)$126,472 
FDIC Certificates of Deposit4,165 — (6)4,159 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper62,031 4 (35)62,000 
Corporate Notes/Bonds143,461 37 (325)143,173 
$396,234 $82 $(512)$395,804 
December 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$150,651 $148 $(204)$150,595 
FDIC Certificates of Deposit4,410 2 (12)4,400 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper78,610 59 (27)78,642 
Corporate Notes/Bonds118,899 281 (143)119,037 
$412,570 $490 $(386)$412,674 
The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of March 31, 2024 and December 31, 2023, the Company held $93.0 million and $77.8 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year.
The aggregate related fair value of investments with unrealized losses as of March 31, 2024 was $253.5 million, which consisted of $81.3 million from U.S. government agency securities, $3.4 million of certificates of deposit, $56.2 million of commercial paper, and $112.6 million of corporate notes/bonds. $37.8 million of the aggregate fair value of investments with unrealized losses as of March 31, 2024 has been held in a continuous unrealized loss position for over 12 months, with the remaining $215.7 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2023, the aggregate related fair value of investments with unrealized losses was $165.2 million. $70.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2023 had been held in a continuous unrealized loss position for over than 12 months, with the remaining $95.1 million held in a continuous unrealized loss position for less than 12 months.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company applies the fair value method under ASC Topic 820, Fair Value Measurements and Disclosures. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
•Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
•Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
•Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company had no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of March 31, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $31.2 million as of March 31, 2024 and $10.7 million as of December 31, 2023 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in certificates of deposit of $60.0 million as of March 31, 2024 is included in cash and cash equivalents. The carrying value of cash held in U.S. government agency securities of $2.5 million and certificates of deposit of $60.0 million as of December 31, 2023 is included in cash and cash equivalents.
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
March 31,
2024		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$31,208 $31,208 $— $— 
U.S. Government Agency Securities126,472 — 126,472 — 
FDIC Certificates of Deposit4,159 — 4,159 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper62,000 — 62,000 — 
Corporate Notes/Bonds143,173 — 143,173 — 
$427,012 $31,208 $395,804 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$10,698 $10,698 $— $— 
U.S. Government Agency Securities150,595 — 150,595 — 
FDIC Certificates of Deposit4,400 — 4,400 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper78,642 — 78,642 — 
Corporate Notes/Bonds119,037 — 119,037 — 
$423,372 $10,698 $412,674 $— 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consists of the following (in thousands):
March 31,
2024		December 31,
2023
Raw materials$34,818 $38,621 
Work in process8,875 4,277 
Finished goods7,074 7,370 
Total50,767 50,268 
Less: Current portion(15,949)(11,647)
Total inventory, non-current$34,818 $38,621 
As of March 31, 2024 and December 31, 2023, the Company has recorded $7.8 million and $7.7 million, respectively, in inventory on the condensed consolidated balance sheets which is subject to supplemental regulatory procedures but believes it is probable that it has future economic benefit.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid and Other Assets
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid and Other Assets Prepaid and Other Assets
Prepaid expenses and other assets consist of the following (in thousands):
March 31,
2024		December 31,
2023
Prepaid operating expenses, non-clinical$28,312 $19,465 
Production campaign deposits23,781 15,127 
Clinical trial advances17,076 11,630 
Prefunded customer programs4,567 3,514 
Total73,736 49,736 
Less: Current portion(66,048)(42,443)
Total other assets$7,688 $7,293 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Right of Use Assets and Lease Liabilities
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Right of Use Assets and Lease Liabilities Right of Use Assets and Lease Liabilities
In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASC Topic 842, Leases, for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029.
The Company has also entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual vehicle leases, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease, which has been recorded as restricted cash on the condensed consolidated balance sheets.
The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of March 31, 2024 and December 31, 2023:
March 31, 2024December 31, 2023
Other information
Weighted average remaining lease term5.0 years5.3 years
Weighted average discount rate9.07 %9.07 %
The following table presents the lease cost for the three-month periods ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Lease cost
Operating lease cost$941$1,085
Variable lease cost411404
Short-term lease cost536672
$1,888$2,161
Maturity analysis under the lease agreements is as follows (in thousands):
Nine months ending December 31, 2024$2,850 
Year ending December 31, 20253,907 
Year ending December 31, 20263,974 
Year ending December 31, 20274,022 
Year ending December 31, 20284,144 
Thereafter1,771 
Total20,668 
Less: Present value discount(4,292)
Total operating lease liability16,376 
Less: Current portion(3,639)
Operating lease liabilities, non-current$12,737 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (BMS), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company has made payments of $10.8 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
Purchase Commitments
The Company enters into certain long-term commitments for goods and services that are outstanding for periods greater than one year. The Company has manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of March 31, 2024, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (API) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory through 2027. The Company has paid deposits of $23.8 million and $15.1 million as of March 31, 2024 and December 31, 2023, respectively, related to these campaigns. Of the $23.8 million balance as of March 31, 2024, $16.2 million is recorded within prepaid expenses and other current assets as the campaigns are expected to be received within one year of the balance sheet date and $7.6 million is recorded within other assets on the condensed consolidated balance sheet as the campaigns are expected to be received after March 31, 2025. Of the $15.1 million balance as of December 31, 2023, $7.9 million is recorded within prepaid expenses and other current assets and $7.2 million is recorded within other assets on the condensed consolidated balance sheet. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs), granted to employees and directors recognized during the three-month periods ended March 31, 2024 and 2023, was comprised of the following (in thousands):
Three Months Ended March 31,
20242023
Inventoriable costs$417 $342 
Selling, general and administrative9,217 6,980 
Research and development4,209 3,117 
Total share-based compensation expense$13,843 $10,439 
Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (the Amended 2018 Plan) and 2019 Inducement Award Plan (the 2019 Inducement Plan) as of March 31, 2024, and changes during the three-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20234,239,982$28.22 5.2 years
Options granted 2024—
Options exercised 2024(461,857)
Options canceled or expired 2024(5,020)
Outstanding at March 31, 20243,773,105$28.99 5.2 years
Vested and expected to vest at March 31, 20243,773,105$28.99 
Exercisable at March 31, 20243,379,986$26.29 4.9 years
The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the three-month period ended March 31, 2024 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20231,645,130$48.92 1.0 year
Time-based RSUs granted in 2024980,422
Time-based RSUs vested in 2024(697,741)
Time-based RSUs cancelled in 2024(12,676)
Outstanding at March 31, 20241,915,135$59.67 1.6 years
As of March 31, 2024, there were $109.6 million of unrecognized compensation costs estimated related to unvested time-based RSUs.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Loss Per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Loss Per Share Loss Per Share
The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three-month periods ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
Stock options3,773,1054,737,963
RSUs2,139,6371,829,155
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net loss $ (15,247) $ (44,053)
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Michael I. Halstead [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
•On March 6, 2024, Robert Van Nostrand, a director of the Company, adopted a Rule 10b5-1 Sales Plan. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 20,000 shares of our common stock until June 28, 2024. These 20,000 shares of our common stock are issuable upon the exercise of stock options held by Mr. Van Nostrand that expire on June 30, 2024.
Robert Van Nostrand [Member]  
Trading Arrangements, by Individual  
Name Robert Van Nostrand
Title director of the Company
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 6, 2024
Arrangement Duration 480 days
Aggregate Available 20,000
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. For the three-month period ended March 31, 2024, 98% of product sales were generated from three major industry wholesalers.
Three individual customers accounted for approximately 37%, 26%, and 35% as well as 37%, 31%, and 29% of product sales for the three-month periods ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company continues to believe that such customers are of high credit quality.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investment Securities (Tables)
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investment Securities
Investment securities consisted of the following (in thousands):
March 31, 2024
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$126,577 $41 $(146)$126,472 
FDIC Certificates of Deposit4,165 — (6)4,159 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper62,031 4 (35)62,000 
Corporate Notes/Bonds143,461 37 (325)143,173 
$396,234 $82 $(512)$395,804 
December 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$150,651 $148 $(204)$150,595 
FDIC Certificates of Deposit4,410 2 (12)4,400 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper78,610 59 (27)78,642 
Corporate Notes/Bonds118,899 281 (143)119,037 
$412,570 $490 $(386)$412,674 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
March 31,
2024		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$31,208 $31,208 $— $— 
U.S. Government Agency Securities126,472 — 126,472 — 
FDIC Certificates of Deposit4,159 — 4,159 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper62,000 — 62,000 — 
Corporate Notes/Bonds143,173 — 143,173 — 
$427,012 $31,208 $395,804 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$10,698 $10,698 $— $— 
U.S. Government Agency Securities150,595 — 150,595 — 
FDIC Certificates of Deposit4,400 — 4,400 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper78,642 — 78,642 — 
Corporate Notes/Bonds119,037 — 119,037 — 
$423,372 $10,698 $412,674 $— 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory (Tables)
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
Inventory consists of the following (in thousands):
March 31,
2024		December 31,
2023
Raw materials$34,818 $38,621 
Work in process8,875 4,277 
Finished goods7,074 7,370 
Total50,767 50,268 
Less: Current portion(15,949)(11,647)
Total inventory, non-current$34,818 $38,621 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid and Other Assets (Tables)
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Assets
Prepaid expenses and other assets consist of the following (in thousands):
March 31,
2024		December 31,
2023
Prepaid operating expenses, non-clinical$28,312 $19,465 
Production campaign deposits23,781 15,127 
Clinical trial advances17,076 11,630 
Prefunded customer programs4,567 3,514 
Total73,736 49,736 
Less: Current portion(66,048)(42,443)
Total other assets$7,688 $7,293 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Right of Use Assets and Lease Liabilities (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Quantitative Information About Operating Leases
The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of March 31, 2024 and December 31, 2023:
March 31, 2024December 31, 2023
Other information
Weighted average remaining lease term5.0 years5.3 years
Weighted average discount rate9.07 %9.07 %
The following table presents the lease cost for the three-month periods ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Lease cost
Operating lease cost$941$1,085
Variable lease cost411404
Short-term lease cost536672
$1,888$2,161
Schedule Of Maturity Analysis Under Lease Agreements
Maturity analysis under the lease agreements is as follows (in thousands):
Nine months ending December 31, 2024$2,850 
Year ending December 31, 20253,907 
Year ending December 31, 20263,974 
Year ending December 31, 20274,022 
Year ending December 31, 20284,144 
Thereafter1,771 
Total20,668 
Less: Present value discount(4,292)
Total operating lease liability16,376 
Less: Current portion(3,639)
Operating lease liabilities, non-current$12,737 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs), granted to employees and directors recognized during the three-month periods ended March 31, 2024 and 2023, was comprised of the following (in thousands):
Three Months Ended March 31,
20242023
Inventoriable costs$417 $342 
Selling, general and administrative9,217 6,980 
Research and development4,209 3,117 
Total share-based compensation expense$13,843 $10,439 
Stock Option Activity
Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (the Amended 2018 Plan) and 2019 Inducement Award Plan (the 2019 Inducement Plan) as of March 31, 2024, and changes during the three-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20234,239,982$28.22 5.2 years
Options granted 2024—
Options exercised 2024(461,857)
Options canceled or expired 2024(5,020)
Outstanding at March 31, 20243,773,105$28.99 5.2 years
Vested and expected to vest at March 31, 20243,773,105$28.99 
Exercisable at March 31, 20243,379,986$26.29 4.9 years
Summary of Information Regarding RSU Activity Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the three-month period ended March 31, 2024 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20231,645,130$48.92 1.0 year
Time-based RSUs granted in 2024980,422
Time-based RSUs vested in 2024(697,741)
Time-based RSUs cancelled in 2024(12,676)
Outstanding at March 31, 20241,915,135$59.67 1.6 years
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Loss Per Share - (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share
The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three-month periods ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
Stock options3,773,1054,737,963
RSUs2,139,6371,829,155
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization - Additional Information (Detail) - Subsequent Event
$ / shares in Units, $ in Millions
 1 Months Ended
Apr. 30, 2024
USD ($)
$ / shares
shares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]  
Shares sold (in shares) | shares 7,876,713
Offering price (in dollars per share) | $ / shares $ 73.00
Aggregate gross proceeds $ 575.0
Net proceeds $ 543.0
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Additional Information (Detail) - segment
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Significant Accounting Policies [Line Items]    
Number of operating segments 1  
Revenue Benchmark | Customer Concentration Risk | Three Major Wholesalers    
Significant Accounting Policies [Line Items]    
Concentration risk (as a percent) 98.00%  
Revenue Benchmark | Customer Concentration Risk | Customer One    
Significant Accounting Policies [Line Items]    
Concentration risk (as a percent) 37.00% 37.00%
Revenue Benchmark | Customer Concentration Risk | Customer Two    
Significant Accounting Policies [Line Items]    
Concentration risk (as a percent) 26.00% 31.00%
Revenue Benchmark | Customer Concentration Risk | Customer Three    
Significant Accounting Policies [Line Items]    
Concentration risk (as a percent) 35.00% 29.00%
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investment Securities - Summary of Investment Securities (Detail) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost $ 396,234 $ 412,570
Unrealized Gains 82 490
Unrealized (Losses) (512) (386)
Estimated Fair Value 395,804 412,674
U.S. Government Agency Securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 126,577 150,651
Unrealized Gains 41 148
Unrealized (Losses) (146) (204)
Estimated Fair Value 126,472 150,595
FDIC Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 4,165 4,410
Unrealized Gains 0 2
Unrealized (Losses) (6) (12)
Estimated Fair Value 4,159 4,400
Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 60,000 60,000
Unrealized Gains 0 0
Unrealized (Losses) 0 0
Estimated Fair Value 60,000 60,000
Commercial Paper    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 62,031 78,610
Unrealized Gains 4 59
Unrealized (Losses) (35) (27)
Estimated Fair Value 62,000 78,642
Corporate Notes/Bonds    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 143,461 118,899
Unrealized Gains 37 281
Unrealized (Losses) (325) (143)
Estimated Fair Value $ 143,173 $ 119,037
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investment Securities - Additional Information (Detail) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Investment securities, available for sale, noncurrent $ 93.0 $ 77.8
Aggregate related fair value of investments with unrealized losses 253.5 165.2
Aggregate fair value of investments with unrealized losses 37.8 70.1
Continuous unrealized losses, value remaining 215.7 $ 95.1
U.S. Government Agency Securities    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 81.3  
Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 3.4  
Commercial Paper    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 56.2  
Corporate Notes/Bonds    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses $ 112.6  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying value of cash held in money market funds $ 31.2 $ 10.7
Cash and Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Certificates of deposits 60.0 60.0
Carrying value of cash held in commercial paper, government securities   2.5
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities measured using quoted prices 0.0 0.0
Assets measured using quoted prices $ 0.0 $ 0.0
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities $ 427,012 $ 423,372
Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 31,208 10,698
Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 126,472 150,595
Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 4,159 4,400
Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 60,000 60,000
Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 62,000 78,642
Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 143,173 119,037
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 31,208 10,698
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 31,208 10,698
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 395,804 412,674
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 126,472 150,595
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 4,159 4,400
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 60,000 60,000
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 62,000 78,642
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 143,173 119,037
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities $ 0 $ 0
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory - Schedule of Inventory, Current (Detail) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 34,818 $ 38,621
Work in process 8,875 4,277
Finished goods 7,074 7,370
Total 50,767 50,268
Less: Current portion 15,949 11,647
Total inventory, non-current 34,818 38,621
Inventory subject to supplemental regulatory procedures $ 7,800 $ 7,700
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Prepaid and Other Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid operating expenses, non-clinical $ 28,312 $ 19,465
Production campaign deposits 23,781 15,127
Clinical trial advances 17,076 11,630
Prefunded customer programs 4,567 3,514
Total 73,736 49,736
Less: Current portion (66,048) (42,443)
Total other assets $ 7,688 $ 7,293
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Right of Use Assets and Lease Liabilities - Additional Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Sep. 30, 2018
Operating Leased Assets [Line Items]    
Term of long term lease 12 months  
Vehicle Lease    
Operating Leased Assets [Line Items]    
Guarantor obligations, value $ 1,750  
NEW YORK    
Operating Leased Assets [Line Items]    
Term of long term lease   14 years 3 months 18 days
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Other information      
Weighted average remaining lease term (in years) 5 years   5 years 3 months 18 days
Weighted average discount rate (as a percent) 9.07%   9.07%
Lease cost      
Operating lease cost $ 941 $ 1,085  
Variable lease cost 411 404  
Short-term lease cost 536 672  
Total lease cost $ 1,888 $ 2,161  
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Leases [Abstract]    
Nine months ending December 31, 2024 $ 2,850  
Year ending December 31, 2025 3,907  
Year ending December 31, 2026 3,974  
Year ending December 31, 2027 4,022  
Year ending December 31, 2028 4,144  
Thereafter 1,771  
Total 20,668  
Less: Present value discount (4,292)  
Total operating lease liability 16,376  
Less: Current portion (3,639) $ (3,612)
Operating lease liabilities, non-current $ 12,737 $ 13,326
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 226 Months Ended
May 31, 2005
Mar. 31, 2024
Mar. 31, 2024
Dec. 31, 2023
Purchase Commitment        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Cash paid   $ 23,800 $ 23,800 $ 15,100
Other current assets   16,200 16,200 7,900
Other assets   7,600 7,600 $ 7,200
Product | Bristol-Myers Squibb Company        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Company made an upfront payment     10,800  
Payment of milestone amount   $ 5,000 $ 5,000  
Obliged to make milestone payments $ 14,750      
License expiration period   10 years    
Product | Bristol-Myers Squibb Company | Minimum        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Royalty payment, percentage (as a percent) 5.00%      
Product | Bristol-Myers Squibb Company | Maximum        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Royalty payment, percentage (as a percent) 9.00%      
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense $ 13,843 $ 10,439
Inventoriable costs    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense 417 342
Selling, general and administrative    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense 9,217 6,980
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense $ 4,209 $ 3,117
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation - Stock Options Activity (Detail) - $ / shares
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]    
Outstanding at beginning of period, Number of Shares (in shares) 4,239,982  
Options granted, Number of Shares (in shares) 0  
Options exercised, Number of Shares (in shares) (461,857)  
Options canceled or expired, Number of Shares (in shares) (5,020)  
Outstanding at end of period, Number of Shares (in shares) 3,773,105 4,239,982
Vested or expected to vest at end of period, Number of Shares (in shares) 3,773,105  
Exercisable at end of period, Number of Shares (in shares) 3,379,986  
Weighted- Average Exercise Price    
Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share) $ 28.22  
Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share) 28.99 $ 28.22
Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share) 28.99  
Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share) $ 26.29  
Outstanding at end of period, Weighted-Average Contractual Life (in years) 5 years 2 months 12 days 5 years 2 months 12 days
Exercisable at end of period, Weighted-Average Contractual Life (in years) 4 years 10 months 24 days  
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) - RSUs - $ / shares
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]    
Outstanding at beginning of year, Number of Shares (in shares) 1,645,130  
Time based RSU's granted, Number of Shares (in shares) 980,422  
Time based RSU's vested, Number of Shares (in shares) (697,741)  
Time based RSU's cancelled, Number of Shares (in shares) (12,676)  
Outstanding at end of year, Number of Shares (in shares) 1,915,135 1,645,130
Weighted-Average Grant Date Fair Value Per Share    
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share) $ 48.92  
Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share) $ 59.67 $ 48.92
Restricted stock outstanding, Weighted-Average Contractual Life (in years) 1 year 7 months 6 days 1 year
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation - Additional Information (Detail)
$ in Millions
Mar. 31, 2024
USD ($)
Time Based Restricted Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation costs related to unvested RSUs $ 109.6
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) - shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Number of anti-dilutive securities excluded from computation of earnings per share (in shares) 3,773,105 4,737,963
RSUs    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Number of anti-dilutive securities excluded from computation of earnings per share (in shares) 2,139,637 1,829,155
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO / " 7'4 !X;"]W;W)K8F]O:RYX;6Q02P$" M% ,4 " !M/:=8N#;$W*D! N&P &@ @ %[V >&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !M/:=84]DK*;(! M !3&P $P @ % XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 143 211 1 false 44 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.intracellulartherapies.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 8 false false R9.htm 0000009 - Disclosure - Organization Sheet http://www.intracellulartherapies.com/role/Organization Organization Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Investment Securities Sheet http://www.intracellulartherapies.com/role/InvestmentSecurities Investment Securities Notes 11 false false R12.htm 0000012 - Disclosure - Fair Value Measurements Sheet http://www.intracellulartherapies.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Inventory Sheet http://www.intracellulartherapies.com/role/Inventory Inventory Notes 13 false false R14.htm 0000014 - Disclosure - Prepaid and Other Assets Sheet http://www.intracellulartherapies.com/role/PrepaidandOtherAssets Prepaid and Other Assets Notes 14 false false R15.htm 0000015 - Disclosure - Right of Use Assets and Lease Liabilities Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities Right of Use Assets and Lease Liabilities Notes 15 false false R16.htm 0000016 - Disclosure - Commitments and Contingencies Sheet http://www.intracellulartherapies.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 0000017 - Disclosure - Share-Based Compensation Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 0000018 - Disclosure - Loss Per Share Sheet http://www.intracellulartherapies.com/role/LossPerShare Loss Per Share Notes 18 false false R19.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 9954472 - Disclosure - Investment Securities (Tables) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables Investment Securities (Tables) Tables http://www.intracellulartherapies.com/role/InvestmentSecurities 22 false false R23.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.intracellulartherapies.com/role/FairValueMeasurements 23 false false R24.htm 9954474 - Disclosure - Inventory (Tables) Sheet http://www.intracellulartherapies.com/role/InventoryTables Inventory (Tables) Tables http://www.intracellulartherapies.com/role/Inventory 24 false false R25.htm 9954475 - Disclosure - Prepaid and Other Assets (Tables) Sheet http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsTables Prepaid and Other Assets (Tables) Tables http://www.intracellulartherapies.com/role/PrepaidandOtherAssets 25 false false R26.htm 9954476 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables Right of Use Assets and Lease Liabilities (Tables) Tables http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities 26 false false R27.htm 9954477 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.intracellulartherapies.com/role/ShareBasedCompensation 27 false false R28.htm 9954478 - Disclosure - Loss Per Share - (Tables) Sheet http://www.intracellulartherapies.com/role/LossPerShareTables Loss Per Share - (Tables) Tables http://www.intracellulartherapies.com/role/LossPerShare 28 false false R29.htm 9954479 - Disclosure - Organization - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail Organization - Additional Information (Detail) Details 29 false false R30.htm 9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 30 false false R31.htm 9954481 - Disclosure - Investment Securities - Summary of Investment Securities (Detail) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail Investment Securities - Summary of Investment Securities (Detail) Details 31 false false R32.htm 9954482 - Disclosure - Investment Securities - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail Investment Securities - Additional Information (Detail) Details 32 false false R33.htm 9954483 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 33 false false R34.htm 9954484 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) Details 34 false false R35.htm 9954485 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) Sheet http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail Inventory - Schedule of Inventory, Current (Detail) Details 35 false false R36.htm 9954486 - Disclosure - Prepaid and Other Assets (Details) Sheet http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails Prepaid and Other Assets (Details) Details http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsTables 36 false false R37.htm 9954487 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails Right of Use Assets and Lease Liabilities - Additional Information (Details) Details 37 false false R38.htm 9954488 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Details 38 false false R39.htm 9954489 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Details 39 false false R40.htm 9954490 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 40 false false R41.htm 9954491 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Details 41 false false R42.htm 9954492 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail Share-Based Compensation - Stock Options Activity (Detail) Details 42 false false R43.htm 9954493 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Details 43 false false R44.htm 9954494 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 44 false false R45.htm 9954495 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Sheet http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Details 45 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration - itci-20240331.htm 4 itci-20240331.htm itci-20240331.xsd itci-20240331_cal.xml itci-20240331_def.xml itci-20240331_lab.xml itci-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "itci-20240331.htm": { "nsprefix": "itci", "nsuri": "http://www.intracellulartherapies.com/20240331", "dts": { "inline": { "local": [ "itci-20240331.htm" ] }, "schema": { "local": [ "itci-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "itci-20240331_cal.xml" ] }, "definitionLink": { "local": [ "itci-20240331_def.xml" ] }, "labelLink": { "local": [ "itci-20240331_lab.xml" ] }, "presentationLink": { "local": [ "itci-20240331_pre.xml" ] } }, "keyStandard": 194, "keyCustom": 17, "axisStandard": 20, "axisCustom": 0, "memberStandard": 28, "memberCustom": 10, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 1 }, "contextCount": 143, "entityCount": 1, "segmentCount": 44, "elementCount": 423, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 439, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 10 }, "report": { "R1": { "role": "http://www.intracellulartherapies.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "unique": true } }, "R3": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "unique": true } }, "R6": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "unique": true } }, "R9": { "role": "http://www.intracellulartherapies.com/role/Organization", "longName": "0000009 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecurities", "longName": "0000011 - Disclosure - Investment Securities", "shortName": "Investment Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurements", "longName": "0000012 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.intracellulartherapies.com/role/Inventory", "longName": "0000013 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.intracellulartherapies.com/role/PrepaidandOtherAssets", "longName": "0000014 - Disclosure - Prepaid and Other Assets", "shortName": "Prepaid and Other Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities", "longName": "0000015 - Disclosure - Right of Use Assets and Lease Liabilities", "shortName": "Right of Use Assets and Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "itci:RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "itci:RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.intracellulartherapies.com/role/CommitmentsandContingencies", "longName": "0000016 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensation", "longName": "0000017 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.intracellulartherapies.com/role/LossPerShare", "longName": "0000018 - Disclosure - Loss Per Share", "shortName": "Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables", "longName": "9954472 - Disclosure - Investment Securities (Tables)", "shortName": "Investment Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.intracellulartherapies.com/role/InventoryTables", "longName": "9954474 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsTables", "longName": "9954475 - Disclosure - Prepaid and Other Assets (Tables)", "shortName": "Prepaid and Other Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables", "longName": "9954476 - Disclosure - Right of Use Assets and Lease Liabilities (Tables)", "shortName": "Right of Use Assets and Lease Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "longName": "9954477 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.intracellulartherapies.com/role/LossPerShareTables", "longName": "9954478 - Disclosure - Loss Per Share - (Tables)", "shortName": "Loss Per Share - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "longName": "9954479 - Disclosure - Organization - Additional Information (Detail)", "shortName": "Organization - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-36", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-36", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail", "longName": "9954481 - Disclosure - Investment Securities - Summary of Investment Securities (Detail)", "shortName": "Investment Securities - Summary of Investment Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "longName": "9954482 - Disclosure - Investment Securities - Additional Information (Detail)", "shortName": "Investment Securities - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "longName": "9954483 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "shortName": "Fair Value Measurements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "longName": "9954484 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail)", "shortName": "Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-83", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-83", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail", "longName": "9954485 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)", "shortName": "Inventory - Schedule of Inventory, Current (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails", "longName": "9954486 - Disclosure - Prepaid and Other Assets (Details)", "shortName": "Prepaid and Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "itci:PrepaidOperatingExpensesNonClinical", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "itci:PrepaidOperatingExpensesNonClinical", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails", "longName": "9954487 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details)", "shortName": "Right of Use Assets and Lease Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "longName": "9954488 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "shortName": "Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail", "longName": "9954489 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "shortName": "Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "longName": "9954490 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-123", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-124", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "unique": true } }, "R41": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "longName": "9954491 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "shortName": "Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-125", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "unique": true } }, "R42": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "longName": "9954492 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail)", "shortName": "Share-Based Compensation - Stock Options Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "unique": true } }, "R43": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "longName": "9954493 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "shortName": "Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-132", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-134", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "unique": true } }, "R44": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "longName": "9954494 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "shortName": "Share-Based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-136", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-136", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "longName": "9954495 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "shortName": "Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-137", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-137", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18", "r515" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r165", "r166" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of premiums and accretion of discounts on investment securities, net", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r67" ] }, "itci_AccruedCustomerProgramsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "AccruedCustomerProgramsCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued customer programs", "label": "Accrued Customer Programs Current", "documentation": "Accrued customer programs current." } } }, "auth_ref": [] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued employee benefits", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated comprehensive (loss) income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r23", "r24", "r59", "r102", "r375", "r398", "r399" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Comprehensive (Loss) Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r10", "r24", "r297", "r300", "r331", "r394", "r395", "r622", "r623", "r624", "r628", "r629", "r630" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r566" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r51" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r281", "r282", "r283", "r406", "r628", "r629", "r630", "r653", "r671" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r572" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r572" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r572" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r572" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r39", "r40", "r249" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r537", "r548", "r558", "r583" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r540", "r551", "r561", "r586" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r572" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r579" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r544", "r552", "r562", "r579", "r587", "r591", "r599" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r597" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of anti-dilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r144" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r28" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r79", "r101", "r120", "r149", "r156", "r160", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r290", "r294", "r313", "r372", "r436", "r515", "r528", "r644", "r645", "r657" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r96", "r104", "r120", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r290", "r294", "r313", "r515", "r644", "r645", "r657" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Assets measured using quoted prices", "verboseLabel": "Available-for-sale investment securities", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r41" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r172" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized (Losses)", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r173" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r170", "r206", "r366", "r633" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Investment securities, available-for-sale", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r167", "r206" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment securities, available for sale, noncurrent", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r99", "r167", "r206" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r594" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r595" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r590" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r590" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r590" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r590" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r590" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r590" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r593" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r592" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r591" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r591" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "itci_BristolMyersSquibbCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "BristolMyersSquibbCompanyMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Bristol-Myers Squibb Company", "label": "Bristol Myers Squibb Company [Member]", "documentation": "Bristol Myers Squibb company." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r87", "r373", "r407", "r431", "r515", "r528", "r618" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r27", "r98", "r488" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r27", "r65", "r118" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r65" ] }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of deposits", "label": "Certificates of Deposit, at Carrying Value", "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [ "r618" ] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of Deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r8", "r522", "r523", "r524", "r525" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r570" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "itci_ClinicalTrialAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "ClinicalTrialAdvances", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical trial advances", "label": "Clinical Trial Advances", "documentation": "Clinical Trial Advances" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r571" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r571" ] }, "itci_CollaborativeAgreementUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "CollaborativeAgreementUpfrontPayments", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Company made an upfront payment", "label": "Collaborative Agreement Upfront Payments", "documentation": "Collaborative Agreement Upfront Payments" } } }, "auth_ref": [] }, "itci_CollaborativeArrangementAmountPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "CollaborativeArrangementAmountPayable", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Obliged to make milestone payments", "label": "Collaborative Arrangement Amount Payable", "documentation": "Collaborative arrangement amount payable." } } }, "auth_ref": [] }, "itci_CollaborativeArrangementLicenseExpirationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "CollaborativeArrangementLicenseExpirationTerm", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License expiration period", "label": "Collaborative Arrangement License Expiration Term", "documentation": "Collaborative arrangement license expiration description." } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r73", "r522", "r523", "r524", "r525" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r72", "r215", "r216", "r483", "r641" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r518", "r519", "r520", "r522", "r523", "r524", "r525", "r628", "r629", "r653", "r670", "r671" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r50" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r50", "r423" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r50" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r50", "r423", "r442", "r671", "r672" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.0001 par value: $175,000,000 shares authorized at March\u00a031, 2024 and December\u00a031, 2023, respectively; $97,477,818 and $96,379,811 shares issued and outstanding at March\u00a031, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r50", "r374", "r515" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r576" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r575" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r577" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r574" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r25", "r107", "r109", "r114", "r368", "r384" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r29", "r31", "r43", "r44", "r164", "r482" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r29", "r31", "r43", "r44", "r164", "r400", "r482" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r29", "r31", "r43", "r44", "r164", "r482", "r606" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r45", "r90" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r29", "r31", "r43", "r44", "r164" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r29", "r31", "r43", "r44", "r164", "r482" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Notes/Bonds", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r507", "r509", "r669" ] }, "itci_CostOfProductSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "CostOfProductSales", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product sales", "label": "Cost Of Product Sales", "documentation": "Cost of product sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r121", "r122", "r231", "r234", "r332", "r493", "r495" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r30", "r164" ] }, "itci_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "CustomerOneMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer One", "label": "Customer One [Member]", "documentation": "Customer one." } } }, "auth_ref": [] }, "itci_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "CustomerThreeMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Three", "label": "Customer Three [Member]", "documentation": "Customer three." } } }, "auth_ref": [] }, "itci_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "CustomerTwoMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Two", "label": "Customer Two [Member]", "documentation": "Customer two." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r634" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of investments with unrealized losses", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r85", "r209", "r501" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Continuous unrealized losses, value remaining", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r85", "r209", "r501" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate related fair value of investments with unrealized losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r84", "r208", "r501" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DepositAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositAssets", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Production campaign deposits", "label": "Deposit Assets", "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement." } } }, "auth_ref": [ "r619" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r620" ] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Deposits Assets, Noncurrent", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r619" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r35" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r247", "r251", "r278", "r279", "r280", "r511" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r532" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r565" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per common share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r115", "r128", "r129", "r130", "r131", "r132", "r137", "r139", "r141", "r142", "r143", "r147", "r304", "r305", "r369", "r385", "r497" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r115", "r128", "r129", "r130", "r131", "r132", "r139", "r141", "r142", "r143", "r147", "r304", "r305", "r369", "r385", "r497" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r136", "r144", "r145", "r146" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation costs related to unvested RSUs", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r652" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "terseLabel": "Share-Based Payment Arrangement, Option [Member]", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r530" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r530" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r530" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r604" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r530" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r530" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r530" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r530" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r94", "r110", "r111", "r112", "r123", "r124", "r125", "r127", "r133", "r135", "r148", "r199", "r200", "r236", "r281", "r282", "r283", "r286", "r287", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r314", "r316", "r317", "r318", "r319", "r320", "r331", "r394", "r395", "r396", "r406", "r462" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r573" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r537", "r548", "r558", "r583" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r534", "r545", "r555", "r580" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r579" ] }, "itci_FDICCertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "FDICCertificatesOfDepositMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "FDIC Certificates of Deposit", "label": "FDIC Certificates Of Deposit [Member]", "documentation": "FDIC certificates of deposit." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r307", "r308", "r311" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r307", "r308", "r311" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r41", "r78" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r12" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r41", "r42" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r232", "r240", "r241", "r242", "r243", "r244", "r245", "r308", "r337", "r338", "r339", "r502", "r503", "r507", "r508", "r509" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r312" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r306" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r232", "r240", "r245", "r308", "r337", "r507", "r508", "r509" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r232", "r240", "r245", "r308", "r338", "r502", "r503", "r507", "r508", "r509" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r232", "r240", "r241", "r242", "r243", "r244", "r245", "r308", "r339", "r502", "r503", "r507", "r508", "r509" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r232", "r240", "r241", "r242", "r243", "r244", "r245", "r337", "r338", "r339", "r502", "r503", "r507", "r508", "r509" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r306", "r312" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r201", "r202", "r203", "r204", "r205", "r207", "r210", "r211", "r233", "r235", "r302", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r383", "r501", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r635", "r636", "r637", "r638" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r541", "r552", "r562", "r587" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r541", "r552", "r562", "r587" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r541", "r552", "r562", "r587" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r541", "r552", "r562", "r587" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r541", "r552", "r562", "r587" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r62", "r446" ] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Grant revenue", "label": "Grant [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r648" ] }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsCurrentCarryingValue", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantor obligations, value", "label": "Guarantor Obligations, Current Carrying Value", "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees." } } }, "auth_ref": [ "r221" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r60", "r82", "r149", "r155", "r159", "r161", "r370", "r379", "r499" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r213", "r214", "r447" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r214", "r447" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r86", "r93", "r134", "r135", "r153", "r285", "r288", "r386" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r5" ] }, "itci_IncreaseDecreaseInAccruedCustomerPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "IncreaseDecreaseInAccruedCustomerPrograms", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accrued customer programs", "label": "Increase Decrease In Accrued Customer Programs", "documentation": "Increase decrease in accrued customer programs." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r625" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued employee benefits", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r607", "r625" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r544", "r552", "r562", "r579", "r587", "r591", "r599" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r597" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r533", "r603" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r533", "r603" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r533", "r603" ] }, "itci_InventoriableCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "InventoriableCostsMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventoriable costs", "label": "Inventoriable Costs [Member]", "documentation": "InventoriableCostsMember." } } }, "auth_ref": [] }, "itci_InventoryCurrentAndNoncurrentNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "InventoryCurrentAndNoncurrentNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Inventory, Current And Noncurrent, Net Of Reserves", "documentation": "Inventory, Current And Noncurrent, Net Of Reserves" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/Inventory" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r212" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r70", "r490" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail_1": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "verboseLabel": "Less: Current portion", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r103", "r489", "r515" ] }, "itci_InventoryNetSubjectToSupplementalRegulatoryProcedures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "InventoryNetSubjectToSupplementalRegulatoryProcedures", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory subject to supplemental regulatory procedures", "label": "Inventory, Net, Subject To Supplemental Regulatory Procedures", "documentation": "Inventory, Net, Subject To Supplemental Regulatory Procedures" } } }, "auth_ref": [] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail_1": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, non-current", "verboseLabel": "Total inventory, non-current", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r619" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r70", "r492" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r70", "r491" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r63", "r152" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Securities", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r609", "r610", "r632" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r465", "r467", "r469", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r520" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r465", "r467", "r469", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r520" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r6" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r324", "r514" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease cost", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Maturity Analysis Under Lease Agreements", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r656" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r330" ] }, "itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due after Year Four", "documentation": "Lessee operating lease liability payments due after Year four." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r330" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r330" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r330" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r330" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Nine months ending December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r656" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r330" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of long term lease", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r655" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r19", "r120", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r291", "r294", "r295", "r313", "r422", "r498", "r528", "r644", "r657", "r658" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r55", "r81", "r377", "r515", "r627", "r639", "r654" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r21", "r97", "r120", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r291", "r294", "r295", "r313", "r515", "r644", "r657", "r658" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities measured using quoted prices", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r41" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r164", "r506", "r647", "r667", "r668" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r246", "r364", "r393", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r485", "r486", "r500", "r504", "r510", "r517", "r646", "r659", "r660", "r661", "r662", "r663", "r664" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r571" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r571" ] }, "itci_MichaelIHalsteadMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "MichaelIHalsteadMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Michael I. Halstead [Member]", "documentation": "Michael I. Halstead" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r246", "r364", "r393", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r485", "r486", "r500", "r504", "r510", "r517", "r646", "r659", "r660", "r661", "r662", "r663", "r664" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r590" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of cash held in money market funds", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r649" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r598" ] }, "stpr_NY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "NY", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NEW YORK", "label": "NEW YORK" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r164", "r506", "r647", "r667", "r668" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r572" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r117" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r117" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r65", "r66", "r67" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r61", "r67", "r83", "r95", "r105", "r108", "r112", "r120", "r126", "r128", "r129", "r130", "r131", "r134", "r135", "r140", "r149", "r155", "r159", "r161", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r305", "r313", "r381", "r444", "r460", "r461", "r499", "r526", "r644" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r571" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r541", "r552", "r562", "r579", "r587" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r569" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r568" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r579" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r598" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r598" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r631" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r149", "r155", "r159", "r161", "r499" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r325", "r514" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r323" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "negatedTerseLabel": "Less: Current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r323" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, non-current", "verboseLabel": "Operating lease liabilities, non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r323" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Right of use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r322" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average discount rate (as a percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r329", "r514" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r328", "r514" ] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasedAssetsLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leased Assets [Line Items]", "label": "Operating Leased Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]", "documentation": "Organization consolidation and presentation of financial statements disclosure." } } }, "auth_ref": [] }, "itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]", "documentation": "Organization consolidation and presentation of financial statements disclosure." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r47", "r76", "r401", "r402" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and Other Assets", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "verboseLabel": "Total other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized (loss) gain on investment securities", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r4", "r9", "r77" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive gain (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r11", "r16", "r106", "r109", "r113", "r314", "r315", "r320", "r367", "r382", "r622", "r623" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive (loss) gain:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "itci_OtherInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "OtherInformationAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Other information", "label": "Other Information [Abstract]", "documentation": "Other information." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r571" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r539", "r550", "r560", "r585" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r542", "r553", "r563", "r588" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r542", "r553", "r563", "r588" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r567" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r64" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r570" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r570" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r569" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r579" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r572" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r568" ] }, "itci_PossibleMilestonePaymentsRemaining": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "PossibleMilestonePaymentsRemaining", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of milestone amount", "label": "Possible Milestone Payments Remaining", "documentation": "Payment of milestone amount." } } }, "auth_ref": [] }, "itci_PrefundedCustomerProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "PrefundedCustomerProgram", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prefunded customer programs", "label": "Prefunded Customer Program", "documentation": "Prefunded Customer Program" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "negatedTerseLabel": "Less: Current portion", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r621" ] }, "itci_PrepaidOperatingExpensesNonClinical": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "PrepaidOperatingExpensesNonClinical", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid operating expenses, non-clinical", "label": "Prepaid Operating Expenses, Non-Clinical", "documentation": "Prepaid Operating Expenses, Non-Clinical" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r15" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Product sales, net", "terseLabel": "Product", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r505" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r162", "r365", "r387", "r388", "r389", "r390", "r391", "r392", "r487", "r505", "r516", "r608", "r642", "r643", "r647", "r667" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r162", "r365", "r387", "r388", "r389", "r390", "r391", "r392", "r487", "r505", "r516", "r608", "r642", "r643", "r647", "r667" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r95", "r105", "r108", "r116", "r120", "r126", "r134", "r135", "r149", "r155", "r159", "r161", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r289", "r292", "r293", "r305", "r313", "r370", "r380", "r405", "r444", "r460", "r461", "r499", "r512", "r513", "r527", "r624", "r644" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r371", "r378", "r515" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r71" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": [ "r48", "r80" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r48", "r80" ] }, "us-gaap_PurchaseCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment", "label": "Purchase Commitment [Member]", "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments." } } }, "auth_ref": [ "r48", "r80" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r567" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r567" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r239", "r246", "r274", "r275", "r276", "r340", "r364", "r393", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r485", "r486", "r500", "r504", "r510", "r517", "r520", "r640", "r646", "r660", "r661", "r662", "r663", "r664" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r239", "r246", "r274", "r275", "r276", "r340", "r364", "r393", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r485", "r486", "r500", "r504", "r510", "r517", "r520", "r640", "r646", "r660", "r661", "r662", "r663", "r664" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r484", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r484", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r534", "r545", "r555", "r580" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r121", "r122", "r231", "r234", "r332", "r494", "r495" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r46", "r284", "r665" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r535", "r546", "r556", "r581" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r536", "r547", "r557", "r582" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r543", "r554", "r564", "r589" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r618", "r626" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r52", "r74", "r376", "r397", "r399", "r404", "r424", "r515" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r94", "r123", "r124", "r125", "r127", "r133", "r135", "r199", "r200", "r281", "r282", "r283", "r286", "r287", "r296", "r298", "r299", "r301", "r303", "r394", "r396", "r406", "r671" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenues, net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r150", "r151", "r154", "r157", "r158", "r162", "r163", "r164", "r237", "r238", "r365" ] }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy." } } }, "auth_ref": [] }, "itci_RightOfUseAssetsAndLeaseLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Right of Use Assets and Lease Liabilities", "label": "Right Of Use Assets And Lease Liabilities [Text Block]", "documentation": "Right of use assets and lease liabilities." } } }, "auth_ref": [] }, "itci_RobertVanNostrandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "RobertVanNostrandMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Robert Van Nostrand [Member]", "documentation": "Robert Van Nostrand" } } }, "auth_ref": [] }, "itci_RoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "RoyaltyPaymentPercentage", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty payment, percentage (as a percent)", "label": "Royalty Payment Percentage", "documentation": "Royalty Payment Percentage" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r598" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r598" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross proceeds", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Offering price (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r164", "r605" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment Securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r38" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r38" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r17", "r56", "r57", "r58" ] }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOperatingLeasedAssetsTable", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leased Assets [Table]", "label": "Schedule of Operating Leased Assets [Table]", "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [] }, "itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Quantitative Information About Operating Leases", "label": "Schedule of Quantitative Information About Operating Leases [Table Text Block]", "documentation": "Schedule of Quantitative Information About Operating Leases" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r248", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r13", "r14", "r37" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Information Regarding RSU Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r529" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r531" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "verboseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Time based RSU's cancelled, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r268" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Time based RSU's granted, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r266" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of year, Number of Shares (in shares)", "periodEndLabel": "Outstanding at end of year, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r263", "r264" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share)", "periodEndLabel": "Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r263", "r264" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value Per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock outstanding, Weighted-Average Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Time based RSU's vested, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r267" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r248", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r257" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r257" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Options canceled or expired, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r650" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r651" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period, Number of Shares (in shares)", "periodEndLabel": "Outstanding at end of period, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r255", "r256" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share)", "periodEndLabel": "Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r255", "r256" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested or expected to vest at end of period, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r271" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r271" ] }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsActivityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsActivityRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period, Weighted-Average Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r36" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at end of period, Weighted-Average Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r75" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r326", "r514" ] }, "itci_SignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "SignificantAccountingPoliciesLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Line Items]", "label": "Significant Accounting Policies [Line Items]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "itci_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Policy Text Block]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "itci_SignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "SignificantAccountingPoliciesTable", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Table]", "label": "Significant Accounting Policies [Table]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r68", "r119" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r22", "r94", "r110", "r111", "r112", "r123", "r124", "r125", "r127", "r133", "r135", "r148", "r199", "r200", "r236", "r281", "r282", "r283", "r286", "r287", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r314", "r316", "r317", "r318", "r319", "r320", "r331", "r394", "r395", "r396", "r406", "r462" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r123", "r124", "r125", "r148", "r365", "r403", "r408", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r521" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r123", "r124", "r125", "r148", "r365", "r403", "r408", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r521" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r538", "r549", "r559", "r584" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services (in shares)", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of stock options and issuances of restricted stock (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r11", "r49", "r50", "r74" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Options exercised, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r49", "r50", "r74", "r260" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services", "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of stock options and issuances of restricted stock", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r11", "r74" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r50", "r53", "r54", "r69", "r425", "r442", "r463", "r464", "r515", "r528", "r627", "r639", "r654", "r671" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r321", "r333" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r321", "r333" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r321", "r333" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r578" ] }, "itci_ThreeMajorWholesalersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "ThreeMajorWholesalersMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Three Major Wholesalers", "label": "Three Major Wholesalers [Member]", "documentation": "Three Major Wholesalers" } } }, "auth_ref": [] }, "itci_TimeBasedRestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240331", "localname": "TimeBasedRestrictedStockUnitsRSUMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Time Based Restricted Stock Units", "label": "Time Based Restricted Stock Units R S U [Member]", "documentation": "Time based restricted stock units." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r570" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r577" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r597" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r599" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r233", "r235", "r302", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r383", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r635", "r636", "r637", "r638" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r600" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r601" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r599" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r599" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r602" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r600" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Agency Securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r496", "r507", "r666" ] }, "us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesSecuritiesAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of cash held in commercial paper, government securities", "label": "US Government Agencies Securities, at Carrying Value", "documentation": "Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r596" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r32", "r33", "r34", "r88", "r89", "r91", "r92" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r327", "r514" ] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VehiclesMember", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vehicle Lease", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in share)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r138", "r143" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r137", "r143" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common shares:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//321/tableOfContent" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org//325/tableOfContent" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 66 0001628280-24-020849-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-020849-xbrl.zip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�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ͯUC*SP,3$4NSK6EO>VH(^)7#^)C3MS,*(:"HZ4A]YZ&V6 M?F?%.O3#\'DX$62;QZ+X4Z!?5-/_UA%]6#CF,YNM@FD5I(=&8L+;KA0VF!KV M.03]F/JD/RSZI+,VT@ 6@)-Q59BOY$$?C)&'Q-P>TMR-G$D-X5'BOAVG$[%K'8NF;TK(JWE4X6)FE[.0\E.QA,-P/A3R/?*23?'S#T/

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end XML 68 itci-20240331_htm.xml IDEA: XBRL DOCUMENT 0001567514 2024-01-01 2024-03-31 0001567514 2024-05-03 0001567514 2024-03-31 0001567514 2023-12-31 0001567514 us-gaap:ProductMember 2024-01-01 2024-03-31 0001567514 us-gaap:ProductMember 2023-01-01 2023-03-31 0001567514 us-gaap:GrantMember 2024-01-01 2024-03-31 0001567514 us-gaap:GrantMember 2023-01-01 2023-03-31 0001567514 2023-01-01 2023-03-31 0001567514 us-gaap:CommonStockMember 2022-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001567514 us-gaap:RetainedEarningsMember 2022-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001567514 2022-12-31 0001567514 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001567514 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001567514 us-gaap:CommonStockMember 2023-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001567514 us-gaap:RetainedEarningsMember 2023-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001567514 2023-03-31 0001567514 us-gaap:CommonStockMember 2023-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001567514 us-gaap:RetainedEarningsMember 2023-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001567514 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001567514 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001567514 us-gaap:CommonStockMember 2024-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001567514 us-gaap:RetainedEarningsMember 2024-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001567514 us-gaap:SubsequentEventMember 2024-04-01 2024-04-30 0001567514 us-gaap:SubsequentEventMember 2024-04-30 0001567514 itci:ThreeMajorWholesalersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001567514 itci:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001567514 itci:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001567514 itci:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001567514 itci:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001567514 itci:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001567514 itci:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001567514 itci:FDICCertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:CertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:CommercialPaperMember 2024-03-31 0001567514 us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001567514 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001567514 us-gaap:CashAndCashEquivalentsMember 2024-03-31 0001567514 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001567514 stpr:NY 2018-09-30 0001567514 us-gaap:VehiclesMember 2024-03-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 2024-03-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2024-03-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MinimumMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MaximumMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2024-01-01 2024-03-31 0001567514 us-gaap:PurchaseCommitmentMember 2024-03-31 0001567514 us-gaap:PurchaseCommitmentMember 2023-12-31 0001567514 itci:InventoriableCostsMember 2024-01-01 2024-03-31 0001567514 itci:InventoriableCostsMember 2023-01-01 2023-03-31 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-03-31 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001567514 2023-01-01 2023-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2024-03-31 0001567514 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001567514 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001567514 itci:MichaelIHalsteadMember 2024-01-01 2024-03-31 0001567514 itci:RobertVanNostrandMember 2024-01-01 2024-03-31 0001567514 itci:RobertVanNostrandMember 2024-03-31 shares iso4217:USD iso4217:USD shares itci:segment pure 0001567514 --12-31 2024 Q1 false P480D 10-Q true 2024-03-31 false 001-36274 INTRA-CELLULAR THERAPIES, INC. DE 36-4742850 430 East 29th Street New York NY 10016 646 440-9333 Common Stock ITCI NASDAQ Yes Yes Large Accelerated Filer false false false 105574855 139819000 147767000 335804000 350174000 1750000 1750000 131157000 114018000 15949000 11647000 66048000 42443000 690527000 667799000 1522000 1654000 12481000 12928000 34818000 38621000 7688000 7293000 747036000 728295000 11532000 11452000 33249000 27944000 69972000 53173000 16409000 27364000 3639000 3612000 134801000 123545000 12737000 13326000 147538000 136871000 0.0001 0.0001 175000000 175000000 97477818 97477818 96379811 96379811 10000 10000 2232325000 2208470000 -1632407000 -1617160000 -430000 104000 599498000 591424000 747036000 728295000 144843000 94731000 23000 575000 144866000 95306000 9900000 6751000 113085000 98923000 42833000 38024000 165818000 143698000 -20952000 -48392000 6064000 4349000 -14888000 -44043000 359000 10000 -15247000 -44053000 -0.16 -0.16 -0.46 -0.46 96875275 96875275 95134694 95134694 -15247000 -44053000 -534000 1492000 -15781000 -42561000 94829794 9000 2137737000 -1477486000 -4190000 656070000 849827 1000 3639000 3640000 408 22000 22000 10439000 10439000 -44053000 -44053000 1492000 1492000 95680029 10000 2151837000 -1521539000 -2698000 627610000 96379811 10000 2208470000 -1617160000 104000 591424000 1097668 9989000 9989000 339 23000 23000 13843000 13843000 -15247000 -15247000 -534000 -534000 97477818 10000 2232325000 -1632407000 -430000 599498000 -15247000 -44053000 132000 134000 13843000 10439000 23000 22000 2343000 1737000 17139000 6356000 499000 4421000 24000000 10557000 80000 -1954000 5305000 1410000 -16799000 -4271000 -10955000 -6340000 -115000 -924000 -34116000 -60066000 81046000 108457000 97225000 91995000 16179000 -16462000 9989000 3640000 9989000 3640000 -7948000 -72888000 149517000 150365000 141569000 77477000 139819000 75727000 1750000 1750000 141569000 77477000 Organization <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg capsules for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company completed a public offering of common stock in which the Company sold 7,876,713 shares of common stock at a public offering price of $73.00 per share for aggregate gross proceeds of $575.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $543.0 million. In order to further its commercial activities and research projects and support its collaborations, the Company may require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and working capital needs for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s products, product candidates and technology and, to a much lesser extent, grant funding.</span></div> 7876713 73.00 575000000 543000000 Summary of Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. For the three-month period ended March 31, 2024, 98% of product sales were generated from three major industry wholesalers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three individual customers accounted for approximately 37%, 26%, and 35% as well as 37%, 31%, and 29% of product sales for the three-month periods ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company continues to believe that such customers are of high credit quality. </span></div>Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div>The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders. 1 1 <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span>, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures. <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies </span></div>The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. For the three-month period ended March 31, 2024, 98% of product sales were generated from three major industry wholesalers. </span></div>Three individual customers accounted for approximately 37%, 26%, and 35% as well as 37%, 31%, and 29% of product sales for the three-month periods ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company continues to believe that such customers are of high credit quality. 0.98 0.37 0.26 0.35 0.37 0.31 0.29 Investment Securities <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">62,031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">62,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,461</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">396,234</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(512)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">395,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,570 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(386)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,674 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of March 31, 2024 and December 31, 2023, the Company held $93.0 million and $77.8 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate related fair value of investments with unrealized losses as of March 31, 2024 was $253.5 million, which consisted of $81.3 million from U.S. government agency securities, $3.4 million of certificates of deposit, $56.2 million of commercial paper, and $112.6 million of corporate notes/bonds. $37.8 million of the aggregate fair value of investments with unrealized losses as of March 31, 2024 has been held in a continuous unrealized loss position for over 12 months, with the remaining $215.7 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2023, the aggregate related fair value of investments with unrealized losses was $165.2 million. $70.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2023 had been held in a continuous unrealized loss position for over than 12 months, with the remaining $95.1 million held in a continuous unrealized loss position for less than 12 months. </span></div>The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">62,031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">62,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,461</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">396,234</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(512)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">395,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,570 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(386)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,674 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 126577000 41000 146000 126472000 4165000 0 6000 4159000 60000000 0 0 60000000 62031000 4000 35000 62000000 143461000 37000 325000 143173000 396234000 82000 512000 395804000 150651000 148000 204000 150595000 4410000 2000 12000 4400000 60000000 0 0 60000000 78610000 59000 27000 78642000 118899000 281000 143000 119037000 412570000 490000 386000 412674000 93000000 77800000 253500000 81300000 3400000 56200000 112600000 37800000 215700000 165200000 70100000 95100000 Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value method under ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of March 31, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $31.2 million as of March 31, 2024 and $10.7 million as of December 31, 2023 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in certificates of deposit of $60.0 million as of March 31, 2024 is included in cash and cash equivalents. The carrying value of cash held in U.S. government agency securities of $2.5 million and certificates of deposit of $60.0 million as of December 31, 2023 is included in cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">62,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">62,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,012</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">395,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">423,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 0 31200000 10700000 60000000 2500000 60000000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">62,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">62,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,012</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">395,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">423,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 31208000 31208000 0 0 126472000 0 126472000 0 4159000 0 4159000 0 60000000 0 60000000 0 62000000 0 62000000 0 143173000 0 143173000 0 427012000 31208000 395804000 0 10698000 10698000 0 0 150595000 0 150595000 0 4400000 0 4400000 0 60000000 0 60000000 0 78642000 0 78642000 0 119037000 0 119037000 0 423372000 10698000 412674000 0 Inventory <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">34,818</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,875</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">50,767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory, non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">34,818</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company has recorded $7.8 million and $7.7 million, respectively, in inventory on the condensed consolidated balance sheets which is subject to supplemental regulatory procedures but believes it is probable that it has future economic benefit.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">34,818</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,875</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">50,767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory, non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">34,818</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 34818000 38621000 8875000 4277000 7074000 7370000 50767000 50268000 15949000 11647000 34818000 38621000 7800000 7700000 Prepaid and Other Assets<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid operating expenses, non-clinical</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">28,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production campaign deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial advances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prefunded customer programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,567</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">73,736</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(66,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,688</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,293 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid operating expenses, non-clinical</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">28,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production campaign deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial advances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prefunded customer programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,567</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">73,736</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(66,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,688</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,293 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 28312000 19465000 23781000 15127000 17076000 11630000 4567000 3514000 73736000 49736000 66048000 42443000 7688000 7293000 Right of Use Assets and Lease Liabilities <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual vehicle leases, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease, which has been recorded as restricted cash on the condensed consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of March 31, 2024 and December 31, 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the lease cost for the three-month periods ended March 31, 2024 and 2023 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">941</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,085</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">411</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">536</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">672</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,161</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity analysis under the lease agreements is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nine months ending December 31, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,639)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,737 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P14Y3M18D P12M P12M 1750000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of March 31, 2024 and December 31, 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the lease cost for the three-month periods ended March 31, 2024 and 2023 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">941</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,085</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">411</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">536</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">672</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,161</span></td></tr></table></div> P5Y P5Y3M18D 0.0907 0.0907 941000 1085000 411000 404000 536000 672000 1888000 2161000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity analysis under the lease agreements is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nine months ending December 31, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,639)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,737 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2850000 3907000 3974000 4022000 4144000 1771000 20668000 4292000 16376000 3639000 12737000 Commitments and Contingencies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Royalty Commitments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (BMS), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company has made payments of $10.8 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Commitments </span></div>The Company enters into certain long-term commitments for goods and services that are outstanding for periods greater than one year. The Company has manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of March 31, 2024, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (API) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory through 2027. The Company has paid deposits of $23.8 million and $15.1 million as of March 31, 2024 and December 31, 2023, respectively, related to these campaigns. Of the $23.8 million balance as of March 31, 2024, $16.2 million is recorded within prepaid expenses and other current assets as the campaigns are expected to be received within one year of the balance sheet date and $7.6 million is recorded within other assets on the condensed consolidated balance sheet as the campaigns are expected to be received after March 31, 2025. Of the $15.1 million balance as of December 31, 2023, $7.9 million is recorded within prepaid expenses and other current assets and $7.2 million is recorded within other assets on the condensed consolidated balance sheet. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements. 10800000 5000000 14750000 0.05 0.09 P10Y 23800000 15100000 23800000 16200000 7600000 15100000 7900000 7200000 Share-Based Compensation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs), granted to employees and directors recognized during the three-month periods ended March 31, 2024 and 2023, was comprised of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventoriable costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,439 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (the Amended 2018 Plan) and 2019 Inducement Award Plan (the 2019 Inducement Plan) as of March 31, 2024, and changes during the three-month period then ended, are summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239,982</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(461,857)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,020)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,773,105</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,773,105</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.99 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,379,986</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9 years</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the three-month period ended March 31, 2024 is summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date<br/>Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,645,130</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 year</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs granted in 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980,422</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs vested in 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(697,741)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs cancelled in 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,676)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,915,135</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.67 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6 years</span></td></tr></table></div>As of March 31, 2024, there were $109.6 million of unrecognized compensation costs estimated related to unvested time-based RSUs. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs), granted to employees and directors recognized during the three-month periods ended March 31, 2024 and 2023, was comprised of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventoriable costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,439 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 417000 342000 9217000 6980000 4209000 3117000 13843000 10439000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (the Amended 2018 Plan) and 2019 Inducement Award Plan (the 2019 Inducement Plan) as of March 31, 2024, and changes during the three-month period then ended, are summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239,982</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(461,857)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,020)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,773,105</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,773,105</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.99 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,379,986</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9 years</span></td></tr></table></div> 4239982 28.22 P5Y2M12D 0 461857 5020 3773105 28.99 P5Y2M12D 3773105 28.99 3379986 26.29 P4Y10M24D Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the three-month period ended March 31, 2024 is summarized as follows: <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date<br/>Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,645,130</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 year</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs granted in 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980,422</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs vested in 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(697,741)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs cancelled in 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,676)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,915,135</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.67 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6 years</span></td></tr></table></div> 1645130 48.92 P1Y 980422 697741 12676 1915135 59.67 P1Y7M6D 109600000 Loss Per Share <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three-month periods ended March 31, 2024 and 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,773,105</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,737,963</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,139,637</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,829,155</span></td></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three-month periods ended March 31, 2024 and 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,773,105</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,737,963</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,139,637</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,829,155</span></td></tr></table></div> 3773105 4737963 2139637 1829155 false <div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On March 6, 2024, Robert Van Nostrand, a director of the Company, adopted a Rule 10b5-1 Sales Plan. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 20,000 shares of our common stock until June 28, 2024. These 20,000 shares of our common stock are issuable upon the exercise of stock options held by Mr. Van Nostrand that expire on June 30, 2024.</span></div> March 6, 2024 Robert Van Nostrand director of the Company true 20000 false false